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Prescription Drug Brand Personality as Perceived by Consumers:  




Brand personality can facilitate the development of meaningful consumer-brand 
relationships and allow consumers to move beyond a product attribute focus. The 
pharmaceutical industry has faced challenging market dynamics in recent years, and the 
outlook for branded prescription drugs remains bleak. In light of the difficulties facing 
this industry, brand personality may be a valuable marketing asset. A study of 483 U.S. 
respondents explored the existence of prescription drug brand personalities as identified 
by consumers. The findings revealed that consumers are in fact able to attribute human 
personality traits to prescription drugs, and a stable and generalizable two-dimensional 
(Competence & Innovativeness) scale was established. The results of a multiple 
regression analysis suggested that brand personality can be created through a number of 
different ways, including brand familiarity, advertisement, and personal experience 
(usage). In addition, a significant relationship between brand personality and likelihood 
to request a prescription was found, providing preliminary support for the hypothesis that 
brand personality can influence consumer purchase behaviour. This research has 
important implications for the expansion of pharmaceutical branding strategies and 
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Chapter 1: Introduction 
The U.S. pharmaceutical industry has witnessed turbulent times in recent years. 
Following robust double-digit annual growth rates, the tides have turned and industry 
dynamics have changed drastically. The economic recession that began in 2007 had a 
significant impact on the health of the industry and initiated a downward spiral. Annual 
growth rates in 2010 were a meager 1.9% (Zhong, 2012).  
The outlook remains bleak for the brand name pharmaceutical industry. The 
current environment continues to be challenging due to stringent government regulations, 
an anticipated loss in the billions of dollars due to pending patent expiries; fierce 
competition from generic products; lack of blockbuster drugs in the pipeline; significant 
increased cost of research and development; and social media and communication 
advancements resulting in more informed, knowledgeable and demanding consumers 
who are acting as key decision makers in healthcare treatment (Blackett & Harrison, 
2001; Schuiling & Moss, 2004; Hall & Jones, 2007). 
The challenging market dynamics have shifted the industry’s attention away from 
traditional marketing strategies that focused on research and development and sales 
initiatives. The quest for innovative strategies that bolster sales has led the industry to 
consider the tried and true branding tactics of the consumer goods segment. Over the 
years, powerhouse brands such as Apple, Coca-Cola, and Harley-Davidson have 
successfully leveraged brand-building strategies to develop sustainable points of 
differentiation. One branding strategy that has gained recognition for its success in 
forming meaningful consumer-brand relationships is the brand personality construct. In 
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light of the difficulties facing the pharmaceutical industry, brand personality may be a 
valuable asset.  
Brand personality can be conceptualized as the symbolic meaning a brand 
acquires (Sung & Kim, 2010) and formally defined as “the set of human personality traits 
that are both applicable to and relevant for brands” (Azoulay & Kapferer, 2003, p. 151). 
The concept was first introduced in the 1960s (Ekinci & Hosany, 2006) and has remained 
central in both academia and practice for decades. The significance of this branding 
strategy can be understood by looking at the tangible outcomes that exist as a result of a 
strong and favorable brand personality, both from a marketer and consumer perspective.  
Brand personality allows marketers to create a distinct and meaningful image in 
the minds of consumers. This allows for product differentiation (Crask & Laskey, 1990); 
contributes to more favorable evaluations when compared to a generic offering (Upshaw, 
1995); and increases brand equity, brand loyalty and brand trust (Sung & Kim, 2010). 
Technological advances and stringent regulations have made it more difficult for 
marketers to differentiate solely on functional product attributes. Consumers expect a 
minimum standard of quality and there are a number of me-too and copycat brands to 
compete with. The creation of a unique and favorable brand personality has the potential 
to enhance marketing effectiveness, particularly in industries that offer generic products 
with similar product characteristics (Geuens, Weijters, & Wulf, 2009). Brand personality 
may add value and prevent substitution (Kapferer, 2012). 
From a consumer perspective, brand personality allows people to connect with 
their brands (Keller, 1993); creates an emotional appeal (Landon, 1974); and increases 
  
3 
the personal meaning of a brand (Levy, 1959). In addition, it can have a positive 
influence on choice (Schiffman & Kanuk, 1997). 
Absolute Vodka is cool, hip and contemporary. Dove is honest and feminine. 
Apple is young and innovative, and Levi’s is rebellious and sensual (Aaker J. , 1997). 
These examples clearly illustrate that brands are often described as humans, endowed 
with personality traits. Research has consistently shown that consumers do not have any 
difficulty in describing their brands in terms of human characteristics (Aaker J. , 1997). 
Bestowing inanimate objects with human characteristics has allowed consumers to bring 
brands to life, build meaningful relationships (Fournier, 1998), and move beyond the 
functional product attribute perspective to a symbolic or self-expressive state (Keller, 
1993).  
Although this phenomenon has been well documented within the consumer goods 
sector (Aaker J. , 1997; Caprara, Barbaranelli, & Gianluigi, 2001), empirical evidence 
suggests that brand personality extends beyond the realm of consumer goods (Ekinci & 
Hosany, 2006; Ekinci & Riley, 2003; Venable, Rose, Bush, & Gilbert, 2005). The aim of 
this study is to examine the existence of prescription drug brand personalities as 
identified by consumers. Can consumers use human personality traits to describe 
prescription drugs such as Viagra, Lipitor, or Advair? Applying the brand personality 
framework to the pharmaceutical industry may have the potential to facilitate product 




Chapter 2: Research Objectives 
The objective of this research is to draw on the established brand personality 
construct to explore the existence of prescription drug brand personalities as identified by 
consumers; develop a theoretical framework of prescription drug brand personality; and 
introduce a reliable and generalizable measurement scale. This research attempted to 
answer the following questions: 
 
(i) Do consumers attribute human personality to prescription drugs?  
(ii) What are the underlying dimensions of prescription drug brand personality?  
 
A deeper understanding of the factors that influence brand personality will provide 
insight into how the brand personality framework can be concretely applied to the 
pharmaceutical industry. The benefits of brand personality may assist pharmaceutical 
marketers to develop targeted consumer branding strategies and facilitate prescription 
drug differentiation. The following secondary research questions were asked: 
 
(iii) What factors influence brand personality? 
a. Advertisement levels: Are consumers more likely to attribute brand 
personality to highly advertised  (versus less advertised) drugs?  
 
b. Familiarity: Are consumers more likely to attribute brand 




c. Personal Experience: Does personal experience with the brand (i.e. 
current or previous use of the drug) increase the likelihood of 
attributing that brand with a personality? 
 
d. Recent Media Exposure: Does recent media exposure increase the 
likelihood of attributing a personality to a particular brand?   
 
(iv) Does brand personality influence the likelihood of requesting a prescription 
from a physician?  
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Chapter 3: Literature Review 
 Branding is a source of competitive advantage (MacLennan, 2004). It can facilitate 
the shift beyond a functional product focus to an emotional level creating strong 
relationships with the brand (Blackett & Harrison, 2001). The American Marketing 
Association defines a brand as “a name, term, sign, symbol, or design, or a combination 
of these intended to identify the goods and services of one seller or group of sellers and to 
differentiate them from those of competition”. This outdated definition falls short in 
today’s fierce competitive environment. Brands are no longer just about creating a point 
of differentiation based on physical attributes. It is an all encompassing concept that 
“symbolizes a long-term engagement, crusade or commitment to a unique set of values, 
embedded into products, services and behaviors, which make the organization, person or 
product stand apart or stand out” (Kapferer, 2012, p. 12).  
 A product offers tangible and functional benefits; however, a brand has the ability 
to move beyond by providing additional tangible (rational) and intangible (emotional) 
values (Blackett & Harrison, 2001). Brands reside in the minds of consumers and a strong 
brand creates a clearly differentiated position. Brands reduce perceived risk, build trust, 
and stimulate excitement that results in preference, long-term commitment, and prevents 
substitution (Kapferer, 2012). Brand assets, as defined by Kapferer (2012), include 
awareness, image, reputation, and perceived brand personalities. These assets will 
produce brand strength (market share, market leadership, loyalty and price premium) that 




Brand Image and Brand Identity 
Brand identity is the way in which the firm wants their brand to be portrayed by 
the public and encompasses the brand’s meaning, aim, and self-image (Kapferer, 2012).  
Brand image on the other hand, is the way in which the public actually perceives the 
brand and interprets the various communications (De Pelsmacker, Geuens, & Van den 
Bergh, 2007). In short, brand identity refers to the senders’ message and brand image is 
how the recipient actually perceives that message. Image is therefore the result and 
interpretation of the brand identity.  
There is an overall consensus among academics that brand personality is an 
integral part of brand identity; however, there is discrepancy with respect to the other 
components of the framework (Geuens, Weijters, & Wulf, 2009). For example, Aaker 
and Joachimsthaler (2000), define the elements of brand identity as (i) the brand as a 
product, (ii) the brand as an organization, (iii) the brand as a person, and (iv) the brand as 
a symbol. More recently, Kapferer (2012) developed the brand identity prism, a graphical 
representation of a brand as a speech flowing from a sender to a receiver. Six key 
dimensions define the prism: physique (physical features and qualities); personality 
(human personality traits, character); relationship (mode of conduct); culture (values); 
reflection (image of typical user); and self-image (how a brand makes consumers feel). 
While the facets of brand identity continue to be debated, the overall consensus is that 
brand identity, and therefore brand personality, is best understood from the sender-side, 
whereas brand image is best understood from the receiver side.  
It is necessary to distinguish between brand identity and brand image (Azoulay & 
Kapferer, 2003) because interrupted communications between the sender and receiver 
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may result in a gap between the intended brand identity and the perceived brand image 
(Geuens, Weijters, & Wulf, 2009). 
Brand Personality 
The origins of brand personality can be directly linked to research in human 
psychology. Personality is a general tendency to behave consistently across various 
situations and can be broadly classified into five stable and enduring dimensions, referred 
to as the Big Five: Extroversion, Agreeableness, Conscientiousness, Emotional Stability, 
and Culture (Sung & Kim, 2010). There are however some fundamental differences 
between human and brand personality (Sung & Tinkham, 2005). Human personality can 
be implied by character traits and general habits, behaviours, attitudes, feelings, beliefs, 
demographic information, and physical appearance (Park, Jaworski, & MacInnis, 1986). 
Brands, on the other hand, are incapable of action and personality must be inferred by 
their physical attributes, functions, user imagery, and situations in which the brand is 
found (Sung & Kim). 
Measuring brand personality. The preliminary research on brand personality 
was somewhat inconsistent, as a concise definition and measurement tool was lacking. 
Previous research relied primarily on ad hoc or human personality scales that were not 
validated within the context of consumer brands (Aaker J. , 1997). Although certain 
human characteristics can be used to describe brands, not all traits are transferrable to 
brands. In an attempt to fill this gap and address the limitations of prior research, Aaker 
(1997) developed the Brand Personality Scale (BPS).  
Aaker defined brand personality as “the set of human characteristics associated 
with a brand” (1997, p. 347) and introduced a systematic, reliable, valid and 
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generalizable measurement scale. The first phases of Aaker’s research focused on 
establishing a brand personality inventory based on human personality traits, marketing 
literature (academic and practitioner), and original qualitative research. A total of 309 
non-redundant candidate personality traits were identified that were subsequently reduced 
to a more manageable number of 114 traits. The next phase of the research was to 
identify the brand personality dimensions as perceived by consumers. Participants were 
asked to imagine that the indicated brand was a person and rate the extent to which the 
114 personality traits described the specific brand.  
Exploratory principal component analysis and Varimax rotation resulted in a 
clearly identifiable five-factor solution with high loadings and communalities for each of 
the traits. These findings suggest that consumers perceive brands to have five distinct 
personalities: Sincerity, Excitement, Competence, Sophistication, and Ruggedness. 
Further analysis was conducted to identify the subcategories or “facets” that are 
representative of these five dimensions. A series of test-retests confirmed the reliability, 
validity, and generalizability of the scale. The final framework consisted of 42 items from 
15 facets grouped into five different factors, as identified in Figure 1 (Aaker J. , 1997).  




Aaker’s (1997) seminal research laid the foundation for subsequent investigations, 
and a number of empirical studies have relied on this scale to expand further on the 
applicability of brand personality in various consumer good product categories and across 
various cultures (Aaker, Benet-Martinez, & Garolera, 2001; Caprara, Barbaranelli, & 
Gianluigi, 2001). Recent studies have identified the existence of brand personalities in 
peripheral industries such as tourism (Ekinci & Hosany, 2006), not-for-profit 
organizations (Venable, Rose, Bush, & Gilbert, 2005), and restaurants (Ekinci & Riley, 
2003).  
Limitations of Aaker’s Brand Personality Scale. While Aaker’s five 
dimensional BPS has served as the leading measurement tool in the past, recent criticism 
(Austin, Siguaw, & Mattila, 2003; Azoulay & Kapferer, 2003) warrants the evaluation of 
alternative scales. Shortcomings of the scale include: (i) the methodological limitations 
resulting from factor analysis (Sweeney & Brandon, 2006); (ii) the scope of the scale 
extends beyond brand personality and includes dimensions of brand identity such as user-
image and socio-demographic characteristics like age or gender (Azoulay & Kapferer); 
(iii) the scales do not allow for negative traits such as unreliability or selfishness (Kaplan, 
Yurt, Guneri, & Kurtulus, 2010); and (iv) the non-generalizability of the scale for a 
specific brand within a specific product category (Austin, Siguaw, & Mattila).  
Alternative measures. Azoulay and Kapferer (2003) suggested that Aaker’s 
definition of brand personality is too broad and encompasses elements of brand identity 
and image. They proposed a more precise definition: “brand personality is the set of 
human personality traits that are both applicable to and relevant for brands” (p. 151). 
Along with the criticism, Geuens, Weijters and De Wulf (2009) developed a new 
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measure of brand personality that is limited to personality traits and excludes functional 
attributes, demographic characteristics, user imagery, user appearance, and brand 
attitudes.  
Geuens, Weijters and De Wulf’s (2009) scale development process began with 
generating an extensive list of personality items taken from Aaker’s BPS (using only 
personality traits), human personality scales, and original qualitative research. A total of 
244 unique items were selected which were then evaluated to determine applicability to 
brands. Any traits not relevant to brands were deleted, resulting in an initial pool of 40 
items. The relevance of these 40 items was assessed through a number of studies, and a 
final five-factor solution comprising 12 items emerged, as detailed in Figure 2.  
 
Figure 2. A New Measure of Brand Personality (Geuens, Weijters, & Wulf, 2009) 
The Pharmaceutical Industry 
The pharmaceutical industry is a complex industry and has unique characteristics 
that distinguish it from the consumer goods sector. Following several years of robust 
double-digit annual growth, the industry slowed dramatically in 2008, largely as a result 
of the economic recession that began in 2007 (Boehringer Ingelheim GmbH, 2012). The 
industry remains in a depressed state as sales in 2010 only grew by 1.9% (Zhong, 2012). 
Over the next year, the overall pharmaceutical market is expected to grow in the range of 
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three to four percent (Boehringer Ingelheim GmbH). Between 2012 and 2017, the brand 
name pharmaceutical industry will only have an annual growth rate of only 0.4% 
compared with the generic sector that is expected to grow at an annual rate of 6.3% 
(Zhong).  
The industry dynamics continue to be challenging due to stringent government 
regulations, pending patent expiries, increased competition from generic product, lack of 
blockbuster drugs in the pipeline, increased costs associated with research and 
development, social media and communication advancements, and finally, more 
informed and knowledgeable consumers who act as key decision makers in healthcare 
treatment (Blackett & Harrison, 2001; Schuiling & Moss, 2004; Hall & Jones, 2007). 
Pharmaceutical versus Consumer Goods Industry. A comparison of the 
pharmaceutical and consumer goods industries identified the following key points of 
differentiation:  
Foundation for success. As proposed by Schuiling and Moss (2004), success 
within the pharmaceutical industry is contingent upon strong research and development, 
aggressive defense of patents, and powerful sales force. The prosperity of a manufacturer 
is heavily dependent on the depth of their manufacturing “pipeline”, and historically little 
attention has been dedicated to the branding process (Blackett, 2001). 
Product life cycle. The pharmaceutical product life cycle is very unique and short 
lived, measured in years rather than decades or centuries (Moss, 2008). Longevity is an 
advantage experienced by powerful and recognized consumer brands, however more or 
less non-existent in the prescription drug realm. 
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As a result of the significant research and development costs, patent protection 
was introduced in order to manage the product life cycle; protect intellectual property 
rights; encourage new drug development; and allow recovery for some of the costs 
incurred during the initial research and development stages (Kvesic, 2008). Patents were 
designed to guarantee exclusivity for up to 20 years, however the profit maximization 
period is in reality much shorter. It may take a number of years before a patented product 
is launched leaving a limited time of approximately 5-8 years for commercialization. 
Following patent expiry, these previously protected products are rarely promoted as 
generic competition, offered at discounted prices, capture significant market share (Moss, 
2001). According to the Institute for Healthcare Informatics, a generic drug will capture 
60% of a brand name drug’s sales volume within six months of patent expiry (Zhong, 
2012). Between 2006 and 2010, drugs that experienced patent expiry represented total 
loss sales of $80 billion, and this is expected to increase to $140 billion between 2012 
and 2017 (Zhong). 
Prescription decision. The prescribing decision is highly complex, with a number 
of parties interacting. Typically the product is prescribed by a physician, dispensed by a 
pharmacist, and used by a third party. Pharmaceuticals is a highly regulated industry, and 
there are a number of other factors that may influence the decision-making process, 
including formularies, insurance institutions, reimbursement decisions, and advice from 
key opinion leaders (Moss, 2008).  
These significant differences between the consumer goods and pharmaceutical 
industries provide support for the development of a prescription drug specific brand 
personality scale.  
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Pharmaceutical versus Over-The-Counter Medications. A distinction between 
over-the-counter (OTC) medication and prescription drugs is necessary. OTC products 
can be advertised directly to consumers without restriction, they are typically not 
prescribed, can be purchased at will, and are not generally reimbursable by health 
insurers (Kapferer, 2012). Given the nature of these products, OTC medications are 
categorized as a consumer good, and share many characteristic. In fact, in Aaker’s 
original research on brand personality, she included Advil (an OTC brand) as a stimulus 
suggesting that OTC brands are considered as consumer goods (Aaker J. , 1997). These 
significant differences between OTC and prescription medications provide support for the 
development of a prescription drug specific brand personality scale.  
Direct to Consumer Advertising (DTCA) 
The pharmaceutical industry has experienced some dramatic changes as a result 
of the legalization of direct to consumer advertising (DTCA). Due to the nature of the 
product and the inherent risks involved, pharmaceutical advertising is heavily regulated 
in order to protect consumers. Up until 1997, advertisers in the United States were only 
permitted to mention the name of the drug being advertised, or the medical condition that 
the drug was designed to treat (Polen, Khanfar, & Clauson, 2009). The legalization of 
DTCA in the United States has relaxed these restrictions and allowed both the medical 
condition and brand name to be disclosed in the same advertisement. This has had a 
dramatic impact on the industry and presented marketers with the opportunity and forum 
to connect directly with patients. DTCA has been a catalyst for the introduction of 
consumer focused branding practices. Although the advertising regulations have been 
eased in the United States, in most countries, such as Canada, it continues to be very 
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restrictive and advertisers are still only allowed to identify either the medical condition or 
the drug name, but not both. 
Direct to consumer advertising continues to be a controversial issue and heavily 
debated amongst pharmaceutical companies, consumers, physicians, and government 
regulators. Following the legalizing of DTCA in the United States, advertising 
expenditures soared and billions of dollars are spent annually on prescription drug 
advertising. In 1997, total DTCA expenditure was approximately $1 billion and it has 
grown exponentially by nearly 400% to $3.97 billion in 2010 (PharmaLive, 2011). In 
2010, Lipitor, a cholesterol-lowering therapy, was the most advertised prescription drug 
with a total expenditure of approximately $250 million. On an aggregate basis between 
2000 and 2010, Lipitor maintained the leadership position as the most advertised 
prescription drug, with a total expenditure of $1.43 billion (PharmaLive, 2011).  
Although DTCA continues to be criticized, those in favor suggest that DTCA 
educates consumers; empowers consumers to take a more active role in healthcare; 
increases treatment for previously undiagnosed conditions; improves public health; and 
reduces health care costs (Blose & Mack, 2009; National Health Council, 2002). On the 
other hand, critics of DTCA suggest that there may be negative consequences on 
healthcare relationships as physicians are pressured to acquiesce to patient demands. 
Research reveals that a typical doctor’s visit changed drastically after the legalization of 
DTCA, with consumers much more likely to request a specific brand name drug (Bloom, 
1999). A survey conducted by the U.S. Food and Drug Administration indicated that 47% 
of U.S. physicians reported feeling “a little to somewhat pressured” to prescribe the 
advertised drug that the patient requested and 28% of physicians said that DTCA can 
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adversely affect the physician-patient relationship (Thomaselli, 2003). Similarly, research 
conducted by Findlay (2002), commissioned by Prevention Magazine in 2000, found that 
32% of respondents who had seen an advertisement for a prescription medication talked 
with their doctor about the advertised medicine and 26% of that group (approximate 8% 
of all 1,222 respondents), asked for a specific medicine. In addition, patient satisfaction, 
patient return intentions, perceptions on the effectiveness of the visit, and intentions to 
comply with the healthcare instructions can be influenced by whether a physician grants 
the patients’ request for a particular brand (Mack, Blose, & Balaban, 2004; Robinson, et 
al., 2004). 
Pharmaceutical Branding Strategies 
 Marketing strategies in the pharmaceutical industry have undergone considerable 
transformation in recent years, primarily as a result of the legalization of DTCA in the 
United States, the increased prevalence of generic drugs, and the lack of blockbuster 
drugs in the pipeline (Hall & Jones, 2007). Challenging market dynamics have 
emphasized the need to develop brands instead of molecules, and the industry has started 
to recognize the advantages of brand-building strategies (Blackett & Harrison, 2001; 
Moss & Schuiling, 2004).  
 Developing a brand focused marketing strategy has the potential to maximize 
profits; protect against similar products by creating a sustainable point of differentiation; 
influence key decision makers to prescribe and pay for the product; facilitate 
communication between the industry and consumers; and increase brand equity resulting 
in premium pricing and increased market share (Blackett, 2001; MacLennan, 2004). 
Nonetheless, once the patent has expired, a branded product does not guarantee customer 
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loyalty, as a number of consumers will switch to a more affordable generic option 
(MacLennan). Pharmaceutical companies are at a crossroads, given that blockbuster 
drugs such as Lipitor, Plavix and Singulair face imminent patent expiry (Zhong, 2012). 
The question remains whether or not these brands are capable of surviving patent expiry 
by creating a sustainable bond with their consumers.  
 Push / Pull strategies. Historically, the majority of promotional activity has been 
focused at the physician and pharmacist level by way of a push strategy (Pinto, Pinto, & 
Barber, 1998). In 2000, pharmaceutical companies spent more that $15 billion promoting 
prescription drugs, with the majority of the spending on doctor detailing ($4 billion), free 
drug samples ($8 billion), and DTCA ($2.5 billion) (Findlay, 2002). The objective of this 
push strategy was to provide pharmacists and physicians with the necessary information 
and incentive to influence their prescribing behavior and ensure that they prescribe a 
particular drug to a patient.  
The legalization of DTCA provided a new avenue for communication directly to 
consumers, and marketers complemented their existing push strategies with a pull 
approach (Pinto, Pinto, & Barber, 1998). Direct to consumer advertising increases 
awareness of branded prescription drugs and directs consumers to seek information from 
their physician about a specific brand. The integration of the pull strategy has lead to 
remarkable results (Parker & Pettijohn, 2005) and millions of consumers have requested 
an advertised drug after being exposed to an advertisement (Handlin, Mosca, Forgione, & 
Pitta, 2003).  
Prescription drugs as brands. In theory, prescription drugs have all the 
necessary elements to make it a brand, including tangible and intangible benefits such as 
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efficacy and trust (Schuiling & Moss, 2004). Pharmaceutical communications have 
focused on product-attributes, highlighting the functionality and technical aspects of the 
product such as efficacy, safety, convenience and cost effectiveness (Blackett & 
Harrison, 2001).  Bell, Wilkes, and Kravitz (2000) conducted a content analysis of 320 
U.S. DTC advertisements from 1989 to 1998 and identified effectiveness, symptom 
control, innovativeness and convenience as the most commonly used appeals.  
The industry has been criticized for focusing too heavily on the product attributes 
and neglecting other important facades of the branding paradigm (Moss, 2001). A study 
by Roth (2003), found that advertising message strategy could have an effect on 
advertising awareness. Following an in-depth analysis of 208 unique print DTC 
advertisements for 36 different medical conditions, researchers concluded that 
advertisements should avoid presenting symptom information. Transformational 
messages that focus on positive end states and desired emotions are more effective in 
increasing awareness for a DTCA drug (Roth, 2003).   
Recent findings suggest that pharmaceutical marketing strategies have in fact 
adopted a more emotional appeal. Frosch, Krueger, Hornik, Cronholm, and Barg (2007) 
conducted a study of product claim television advertisements aired in 2004 and found 
that 100% of ads used a rational appeal such as describing the product indication, and that 
almost 95% used positive emotional appeal typically depicted by a happy character after 
taking the medication. Approximately two thirds used a negative emotional appeal 
showing characters in a fearful state prior to using the product, and almost one-third 
incorporated humor.  
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Until recently, the pharmaceutical industry has focused solely on the product-
attributes; therefore managing products and not brands (Moss, 2008). Pharmaceutical 
marketing practitioners and academics have recognized the importance of creating and 
managing pharmaceutical brands and are moving beyond the limited scope of the 
product. The competitive nature of the industry and increased prevalence of generic 
offerings makes it extremely difficult to differentiate on product specific characteristics. 
Marketers are faced with the task of creating a deeper meaning and emotional sentiment 
towards their brands. Blackett (2001, p. 13) stated that a powerful brand will create a 
competitive advantage for pharmaceuticals and “in the 21st century, branding ultimately 
will be the only unique differentiator between companies. Brand equity is now a key 
asset”. 
Hypothesis Development 




In light of the industry dynamics and inherent characteristics of the 
pharmaceutical sector, consideration is being given to brand-building, thus moving 
beyond the traditional functional attributes and creating expressive or emotional values 
(Hall & Jones, 2007). Although preliminary, there is evidence to suggest that the brand 
personality construct may be generally applied to pharmaceutical products. Research 
conducted by Kapferer (1998; 2012) concludes that generalist doctors and specialists are 
able to attribute human personality traits to medicines and there is a correlation between 
prescription levels and certain personality traits. Similarly, a recent survey conducted in 
Mumbai on the existence of brand personalities of some leading over-the counter 
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pharmaceutical brands, revealed that consumers do associate brand personalities to over-
the-counter medicines (Mala, 2011).   
These findings are notable; however, they do not address the specific research 
question regarding the existence of brand personality in prescription drugs as identified 
by consumers. Kapferer’s research focused exclusively on physicians and specialists, not 
consumers and the study by Expresspharmaonline used over-the-counter medications that 
are considered to be akin to consumer goods (Kapferer, 2012). The current state of 
research has provided a foundation for further investigation into the applicability of the 
brand personality construct to the pharmaceutical industry. 
 
H2:  Prescription drugs will be described by personality traits associated with 
Competence, such as reliable, successful, and intelligent.  
 
 
Research by Batra, Lenk, and Wedel (2006) suggests that brand personality 
characteristics are influenced by the nature of the product category. In other words, entire 
product categories, not just the individual brands within them, possess a common 
personality. Personality may, therefore, be described at both the product category and 
brand level.  
Using Aaker’s five dimensional brand personality scale as the foundation, 
Maehle, Otnes, and Supphellen (2011) found that specific brand personality dimensions 
are associated with particular product categories: Sincere brands typically share family-
related associations and high morals; Exciting brands are experiential and elicit exciting 
feelings; Competent brands are mostly related to expertise and quality; Sophisticated 
brands are typically feminine in nature; whereas Rugged brands are more masculine. In 
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addition, performance is particularly important to the Sincerity and Competence 
dimensions. Within the context of prescription medications, expertise, quality, and 
performance are of utmost importance to consumers. It is, therefore, reasonable to 
suggest that consumers’ brand personality perceptions of prescription drugs will relate 
most closely to the Competence dimension.  
Brand personality will be influenced by the benefits (functional, symbolic, or 
experiential) associated with the brand: Perceptions of Competence are mainly the result 
of strong functional benefits, such as quality (Maehle, Otnes, & Supphellen, 2011). Until 
recently, pharmaceutical products have been primarily marketed based on the 
functionality and technical aspects of the product such as efficacy, safety and 
convenience (Blackett, 2001; Friedman & Gould, 2007; Hall & Jones, 2007). Consumers 
are particularly interested in the performance and problem-solving capabilities of their 
prescription medications, and Competence associations can facilitate the consumers’ 
ability to evaluate the functional benefits of a product (Maehle, Otnes, & Supphellen, 
2011). 
 
H3a:  Consumers are more likely to attribute brand personality to prescription 
drugs that are highly familiar. 
 
H3b:  Consumers are more likely to attribute brand personality to prescription 
drugs that are heavily advertised.  
 
H3c:  Consumers are more likely to attribute brand personality to prescription 
drugs for which they have recently seen an advertisement. 
 
H3d:  Consumers are more likely to attribute brand personality to prescription 




Brand personality can be formed through direct or indirect experience with the 
brand (Aaker J. , 1997). Direct experience, current or prior usage of the prescription 
medication, will provide consumers with the opportunity to develop a distinct brand 
personality. Alternatively, consumers’ perceptions of brand personality can be created 
indirectly by way of the marketing mix (Batra, Lehmann, & Singh, 1993).  
Brands reside in the minds of consumers and it is the integrative marketing 
strategies that bring these objects to life (Fournier, 1998). Consumers will develop brand 
meaning through the brand communication strategies, sales promotions and media 
advertisements, as well as through the price, distribution channels, and packaging (Batra, 
Lehmann, & Singh, 1993). The strength of the brand’s personality will be improved when 
all elements of the marketing mix are aligned and deliberately communicate a consistent 
message (Batra, Lehmann, & Singh).  
The foregoing research supports the hypotheses that consumers will be more 
likely to attribute brand personality to prescription drugs that are highly familiar; are 
heavily advertised; for which they have recently seen an advertisement; or for which they 
have had personal experience. 
 
H4:  Consumers are more likely to request a prescription for a brand for which 
they have perceptually defined a clear brand personality.  
 
 
Brand personality allows people to connect with their brands (Keller, 1993). It 
creates an emotional appeal (Landon, 1974); increases the personal meaning of a brand 
(Levy, 1959); and, can have a positive influence on choice (Schiffman & Kanuk, 2004). 
The legalization of DTCA has resulted in more consumers requesting a specific brand 
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name drug from their healthcare providers (Bloom, 1999). It is, therefore, more likely 
that prescription drugs that have forged strong and favorable brand associations, such as 
brand personality, are more appealing to consumers and therefore more likely to be 
requested from doctors.  
Prior literature suggests that consumers will prefer brands that have an image and 
personality that is congruent with their own personality (Sirgy, 1982; Malhotra, 1988; 
Dolich, 1969). This phenomenon is known as the self-concept theory and is useful in 
explaining consumers’ choice. Self-concept has been defined as “the totality of the 
individuals’ thoughts and feelings having reference to themselves as subjects as well as 
objects” (Malhotra, 1988, p. 7). It is a multidimensional system that considers the actual 
self (the person that I actually am), the desired self (who I would like to be), and the 
social self (how I want others to see me).  
Escalas and Bettman (2003) suggested that brands and possessions could fulfill 
psychological needs such as creating one’s self-concept, expressing self-identify, and 
asserting individuality. Consumers will actively seek brands that will express and 
reinforce their self-concept and engage in behavior that is consistent with their view of 
self (either the actual, desired, or social self) (Batra, Lehmann, & Singh, 1993). For 
example, BMW conveys an image of success and performance and allows consumers to 
portray a self-image that is consistent with these desirable characteristics. Brand 
personality is an effective communication mechanism through which consumers can 
express their sense of self, both to themselves and to others (Batra, Lehmann, & Singh). 
It conveys information on a typical user, as well as the type of feelings and emotions that 
a consumer can expect to feel when consuming the brand (Batra, Lehmann, & Singh). 
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Chapter 4: Study Design & Methodology 
The research was conducted in a number of stages. Four pretests preceded the 
final consumer survey: 
 Pretest 1: To select the appropriate sample for the study;  
 Pretest 2: To select the brands for the study; 
 Pretest 3 & 4: To generate a list of personality traits applicable to prescription 
medication.  
Pretest 1: Selecting the Subjects 
The ability to attribute brand personality is contingent on the familiarity and 
salience of the product. If consumers are not familiar with a brand, they will not be able 
to attribute a personality to the specific brand (Aaker J. , 1997). As a result, two criteria 
guided the selection of subjects for this study: country of residence and age. The study 
focused exclusively on residents of the United States over the age of 35.  
A sample of the U.S. population was selected because direct to consumer 
advertising is legalized in the United States. Consumers from the United States have 
greater exposure to prescription drug publicity and are likely to have greater awareness 
and familiarity with the selected prescription drug brands.  
Brand familiarly is dependent on salience of the product, and the demographic 
profile of most prescription medication users, are people over the age of 35, an older, 
non-student population was appropriate within the context of this study. A small 
convenience sample of 20 respondents were asked to identify how many prescription 
medications they were familiar with, of a predetermined list of 15 drugs. The results 
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indicated that respondents over the age of 35 (M = 4.3) were more familiar than younger 
respondents (M = 3.2).  
Pretest 2: Selecting the Stimulus  
Aaker (1997) identified three criteria for the selection of brands in her study: 
brands were salient and well known; had a variety of personality types; and were selected 
from a diverse range of product categories (including both utilitarian and symbolic). 
These criteria ensured that consumers were sufficiently familiar with the brands to 
attribute a brand personality and enhanced the scope and generalizability of the scale. 
Within the context of this study, similar criteria guided the selection of brands. 
Consumers become familiar with prescription drugs both indirectly through DTC media 
exposure and directly through usage. Therefore, in order to ensure brand familiarity, 
candidate brands were identified based on two sources: (i) most advertised drugs 
(measured based on 2010 annual media expenditure); and (ii) most prescribed drugs 
(based on 2010 annual sales). See Appendix A for full list of drugs.  
As expected, there were a number of communalities between the two sources, and 
a total of 31 unique drugs were identified as potential candidates. Brand selection 
occurred in three steps:  














(ii) The preceding list was supplemented by 5 brands that only appeared on the 
list of most heavily advertised drugs. Media exposure was weighted more 
heavily in the selection process (versus prescription levels), as mass 
communication strategies have the ability to reach a wider target audience, 







(iii) The list of most prescribed drugs was reviewed and the top eight most 
prescribed drugs were already included in the previous list, with the exception 
of the second most heavily prescribed drug. Although advertising has the 
ability to reach a wide range of consumers, brand familiarity also occurs 
through usage. It was therefore deemed appropriate to include the second most 
heavily prescribed drug, Nexium. 
 
The inclusion of medications designed for a range of ailments may increase the 
generalizability of the findings. Life-threatening illnesses such as high-cholesterol and 
allergy / respiratory conditions, as well as non-life threatening and non-painful conditions 
such as erectile dysfunction (ED) were included in the analysis.  
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Procedures. Pretest two (n=75) was conducted in order to assess respondents’ 
familiarity with the proposed brands. Data were collected via online questionnaire 
developed through FluidSurvey.com and administered by CanView.com (both companies 
are Canadian based and adhere to the Canadian research standards such as the Market 
Research and Intelligence Association (www.mire-arim.ca)). CanView sent an email 
invitation to any participants registered in their panel who qualified for the study. 
Participants received monetary compensation if they successfully completed the 
questionnaire. Participants were assured that the data was anonymous and that personally 
identifiable information was not at risk. 
The list of 15 prescription medications was provided to respondents who were 
asked to indicate which brands they were very familiar with. There were no limitations 
on the number of drugs that could be selected, and respondents were provided with the 
option to select that they were not very familiar with any of the indicated brands. Within 
the context of this question, very familiar was defined as: (i) you know which medical 
condition the drug is designed to treat; and (ii) you would rate your familiarity either 4 or 
5 on a scale of 1 to 5 (1 being very unfamiliar, and 5 being very familiar). 
Results. A total of 75 respondents completed the questionnaire. The sample was 
relatively equally distributed between males and females (49% and 51% respectively). 
The age range was fairly balanced, with a slight preference towards the 45-54-age 
category. Fifteen respondents (20%) indicated that they were not very familiar with any 
of the indicated prescription drugs. Of the 60 respondents that reported being familiar 
with at least one prescription drug, the average number of very familiar brands was 4.8.   
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The brand familiarity results are reported in Table 1. Subjects of the pretest were 
familiar with many of the 15 brands that were presented. All brands were therefore 
retained for the final study.  
 
Table 1 
Prescription Drug Brand Familiarity (pretest results) 
 
Pretest 3 & 4: Brand Personality Trait Generation 
As this was the first study investigating the applicability of consumer-based 
prescription drug brand personality, the first step was to determine which brand 
personality traits were most appropriate for prescription medication. Brand personality 
trait generation occurred in two phases. The objective of Phase 1 was to compare two 
established brand personality scales (the Aaker 1997 Brand Personality Scale versus the 
Geuens, Weijters and De Wulf 2009 New Measure of Brand Personality); and the goal of 

















Not familiar with any brands 20% 15
Note. n = 75
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Phase 1: Established brand personality scales. Preliminary brand personality 
research relied primarily on ad-hoc scales of human personality, however as this 
construct became widespread, tailored brand personality scales emerged in the literature 
and in practice. Aaker’s (1997) Brand Personality Scale was the first attempt to measure 
brand personality. Despite recent criticism regarding the generalizability and broad 
definition on which the scale is based, it continues to be highly recognized by 
practitioners and academics alike. 
In recent years, a number of other brand personality scales have been developed, 
with one of particular interest: the Geuens, Weijters and De Wulf (2009) new measure of 
brand personality. This scale is based on a more precise definition of brand personality 
and excludes any non-personality traits such as gender, age, and social class. The authors 
propose that the scale is generalizable to other product classes and is suitable for analysis 
of an industry (i.e. between-brand within-category comparisons). The scale has gained 
academic credibility and is published in the latest edition of the Handbook of Marketing 
Scales (Haws, Bearden, & Netemeyer, 2011). 
Procedures. Data were collected in conjunction with pretest number two via 
online questionnaire developed through FluidSurvey.com and administered by 
CanView.com. Respondents (n=50) were provided with a list of 52 unique personality 
traits and asked to indicate if the traits were descriptive of any prescription medication. 
Personality traits were generated from both Aaker’s scale (42 individual traits), and 
Geuens, Weijters and De Wulf’s scale (12 individual traits). Two traits, down-to-earth 
and sentimental, appeared on both scales resulting in a total of 52 traits. See Table 2 for 
the entire list of personality traits.  
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Participants were instructed to think of prescription medications in general, as the 
focus was not on any one particular brand. In order to ensure that participants were clear 
on what was considered prescription medication, the following definition was provided: 
 
A prescription medication is a medical drug that has been 
prescribed by a physician. It cannot be obtained without a 
prescription. Over-the-counter drugs, such as Advil, are not 
considered prescription drugs. 
 
 
Results. The subjects were a subset (n=50) of the participants included in the 
second pretest (n=75). The demographic profiles were therefore consistent with the 
previous study. Table 2 lists the traits tested and the corresponding frequency scores. 
 
Table 2 
Frequency Scores of Personality Traits Identified as Descriptive (Aaker & Geuens, 
Weijters and De Wulf) 
 
Traitsa Percentage Traitsa Percentage Traitsa Percentage
Reliable (A) 61% Contemporary (A) 22% Down-to-earth (A/G) 9%
Up-to-date (A) 48% Honest (A) 20% Cheerful (A) 7%
Successful (A) 46% Tough (G) 20% Sentimental (A/G) 7%
Innovative (G) 41% Aggressive (A) 20% Daring (A) 7%
Hard working (A) 39% Bold (G) 15% Trendy (A) 7%
Stable (G) 37% Sincere (A) 15% Spirited (A) 7%
Responsible (G) 35% Wholesome (A) 13% Charming (A) 7%
Unique (A) 30% Secure (A) 13% Masculine (A) 7%
Intelligent (A) 28% Smooth (A) 13% Good looking (A) 4%
Technical (A) 28% Imaginative (A) 11% Young (A) 4%
Dynamic (G) 28% Cool (A) 11% Rugged (A) 2%
Original (A) 26% Family-Oriented (A) 9% Small-town (A) 2%
Confident (A) 26% Exciting (A) 9% Upper class (A) 2%
Simple (G) 26% Independent (A) 9% Glamorous (A) 2%
Active (G) 24% Corporate (A) 9% Outdoorsy (A) 2%
Friendly (A) 22% Feminine (A) 9% Western (A) 2%
Real (A) 22% Ordinary (G) 9%
Leader (A) 22% Romantic (G) 9%
Note: n=50
a (A) refers to traits originating from Aaker's scale, and (G) refers to traits originating from Geuens' scale
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The personality traits were ranked based on the frequency distribution. A visual 
comparison revealed that one scale was not more applicable to prescription drugs. Given 
the primary research objective of identifying the underlying dimensions of brand 
personality, it was necessary to select the traits that were most applicable to prescription 
drugs, regardless of scale origin. The two scales were merged and the highest scoring 
personality traits were retained for further analysis. It was necessary to eliminate certain 
items to ensure that the scale remained manageable. Consistent with the Aaker reduced 
15-item scale, and the Geuens, Weijters and De Wulf 12-item scale, a total of 14 items 
were retained, corresponding to a cutoff frequency score of 25%.  
Phase 2: Supplementary personality traits. Following the results of the Phase 1 
trait generation test, a second pretest was conducted in order to determine if there were 
any supplementary personality traits that should be included in the analysis. A total of 40 
additional traits were identified as potential candidates from two complementary sources: 
(i) Kapferer’s research on prescription medication brand personality from the perspective 
of generalist doctors or specialists (1998), and (ii) established Human Personality Scales 
(Cattell, Marshall, & Georgiades, 1957; Goldberg, 1992).  
Kapferer’s brand personality scale. Preliminary research by Kapferer (1998) 
suggested that the brand personality construct could be generally applied to 
pharmaceutical products. The research concluded that generalist doctors and specialists 
are able to attribute human personality traits to medicines and there is a correlation 
between prescription levels and certain personality traits. The scale included a total of 15 
personality traits, that were all found to be highly statistically significant to prescription 
levels with the exception of four traits: caring, rational, close, and elegant. Although 
  
32 
Kapferer’s research focused exclusively on generalist doctors and specialists, physicians 
are also consumers and may respond to advertisements on more than a professional level. 
The personality traits used in Kapferer’s research may translate to the study of 
consumers’ perceptions of prescription drug brand personality. 
Human personality scales. The origins of the brand personality construct can be 
directly linked to research in human psychology. Although there are similarities between 
human and brand personality, they are not explicitly interchangeable (Aaker J. , 1997). 
Aaker’s brand personality research identified three brand personality dimensions, 
Sincerity, Excitement, and Competence, which were consistent with the “Big Five” 
human personality dimensions, Agreeableness, Extraversion, and Conscientiousness. 
Two dimensions, Sophistication and Ruggedness, were not consistent (Aaker J. , 1997). 
These findings suggest that there may be additional human personality traits that are 
relevant to prescription drug brand personality that were not included within the 
established brand personality scales.  
A second concern with established brand personality scales is that negative traits 
are rarely included. Personality traits such as selfish or unreliable can be used to describe 
humans, and potentially extend to brands (Kaplan, Yurt, Guneri, & Kurtulus, 2010). The 
lack of negative traits in brand personality scales limits the characterization to a positive 
perspective and ignores any negative associations. The unique characteristics that 
distinguish the pharmaceutical industry from the consumer good sector may require the 
inclusion of supplementary human personality traits, both positive and negative in nature.  
In order to capture all potential brand characterizations (positive and negative), 
and to ensure a robust analysis, additional personality traits were generated from the Big 
  
33 
Five model of human personality and Raymond Cattell’s 16 Personality Factors. Recent 
television and print advertisements for prescription medications were carefully reviewed 
to identify consistent terminology, themes, messages, visuals, or signals. A number of 
personality traits consistently emerged such as reliable, serious, dependable, stern, and 
solution oriented. The relevance of these additional traits was supported by an interview 
with an expert in the pharmaceutical industry very familiar with the brand personality 
construct. A total of 25 additional human personality traits were identified as potential 
scale items, as detailed in Table 3. 
Procedures. Consistent with the previous pretests, data was collected via online 
questionnaire developed through FluidSurvey.com and administered by CanView.com. 
Respondents (n=25) were provided with a list of 40 unique personality traits and asked to 
indicate if they thought that the traits were descriptive of any prescription medication. 
Participants were instructed to think of prescription medications in general, as the focus 
was not on any particular brands. A definition of prescription medication was once again 
provided to ensure that participants did not include over-the-counter medications in their 
assessment.  
Results. The subjects were a subset (n=25) of the participants included in the 
second pretest (n=75). The demographic profiles were therefore consistent with the 
previous studies. A total of eight personality traits exceeded the minimum frequency 
score of 25%, as established in the previous pretest. These complementary traits were 
combined with the 14 traits generated in Phase 1, resulting in a total of 22 personality 
traits for the main study. 
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A notable finding of this pretesting was that negative personality traits such as 
shallow; unintelligent; impersonal; unkind; irresponsible, or unfriendly were not 
considered to be characteristic of prescription medications. 
 
Table 3  
Frequency Scores of Personality Traits Identified as Descriptive (Kapferer & Human 
Personality Scales) 
 
Main Study: Prescription Drug Brand Personality 
Subjects. Consistent with the pretests, two criteria guided the selection of 
subjects for this study, country of residence and age. The study focused exclusively on 
U.S. residents over the age of 35. In order to ensure the generalizability of the findings, 
the sample was balanced based on gender, age, and income distribution. 
Procedure. Data was once again collected via online questionnaire developed 
through FluidSurvey.com and administered by CanView.com. The survey was designed 
as follows: 
Traitsa Percentage Traitsa Percentage Traitsa Percentage
Dependable (H) 62% Cold (K) 14% Unkind (H) 5%
Serious (H) 52% Empathetic (K) 14% Careless (H) 5%
Caring (K) 43% Unstable (H) 14% Anxious (H) 5%
Precise (H) 43% Cooperative (H) 14% Impersonal (H) 5%
Practical (H) 43% Prudent (K) 10% Adventurous (H) 5%
Solution Oriented (H) 38% Serene (K) 10% Close (K) 0%
Optimistic (K) 33% Dominant (H) 10% Elegant (K) 0%
Resourceful (H) 29% Undependable (H) 10% Class (K) 0%
Generous (K) 24% Distrustful (H) 10% Nonconforming (H) 0%
Rational (K) 19% Conscientious (H) 10% Shallow (H) 0%
Calm (K) 19% Unfriendly (H) 5% Unintelligent (H) 0%
Sympathetic (H) 19% Stern (H) 5% Outgoing (H) 0%
Creative (K) 14% Irresponsible (H) 5%
Hard (K) 14% Unsentimental (H) 5%
Note: n=25
a (H) refers to traits originating from the Human Personality scale, and (K) refers to traits originating from Kapferer's scale
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Part 1: Screening questions. Respondents were presented with the following 
screening questions: 
(i) Consent: The terms and conditions of the questionnaire were presented and 
candidate respondents were required to confirm their agreement prior to 
proceeding with the questionnaire.  
(ii) Gender: In order to ensure an even distribution between males and females, 
respondents were required to confirm their gender at the beginning of the 
survey. 
(iii) Age: Only respondents over the age of 35 were eligible. Any respondent under 
the age of 35 was dismissed.  
(iv) Prescription Drug Brand Familiarity: Respondents were provided with a list 
of 15 prescription drugs and asked to indicate which brands they were familiar 
with. Within the context of this study, familiar was defined as: (i) you know 
which medical condition the drug is designed to treat; and (ii) you would rate 
your familiarity either 4 or 5 on a scale of 1 to 5 (1 being very unfamiliar, and 
5 being very familiar). Subsequently, respondents were asked to list the five 
brands they were most familiar with.  
Brand familiarity was identified as an important criterion of this survey. 
Respondents needed to be sufficiently familiar with a brand in order to 
attribute a brand personality. Given the targeted nature of prescription drugs, 
consumers in general will be less familiar with these brands than consumer 
good brands. This challenges the development of a generalizable scale, 
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however, in order to ensure the integrity of the study, it was necessary to only 
include respondents that were familiar with the drugs. 
 
Part 2: Main questionnaire: Respondents were assigned one of the five brands 
they rated as most familiar and asked to answer a sequence of questions pertaining to 
(i) brand personality, (ii) personal experience, and (iii) intentions to request a 
prescription from a physician. Once the questionnaire was completed for the first 
brand, the second familiar brand was assigned and respondents were asked to 
complete the questionnaire again. This process continued until the questionnaire had 
been completed for a total of five brands. In order to gather sufficient individual 
brand ratings, each respondent was required to answer the questionnaire for a 
minimum of five prescription drugs. In the event that a respondent was not familiar 
with five brands, they were not permitted to complete the questionnaire. To minimize 
the risk of fatigue, each respondent was only required to complete the questionnaire 
for a maximum of five different brands.  
Respondents were provided with the following instructions adapted from Aaker’s 
original research:  
 
The following adjectives are mostly used to describe characteristics of 
people in daily life. However, some of them can be used to describe 
products, services, or prescription medications. This may sound 
unusual, but we would like you to think of (BRAND X) as if it was a 
person. We are interested in finding out which personality traits or 
human characteristics come to mind. To assist you, we have 
preselected 22 personality traits, and would ask that you please 
indicate the extent to which you think that each of the personality 
traits describe (BRAND X). 
  
37 
For example, you might think that the human characteristics 
associated with Pepto Bismol are kind, warm, caring, soothing, 
gentle, trustworthy and dependable. The human characteristics 
associated with Dr. Pepper might be non-conforming, fun, interesting, 
exciting, and off-beat.  
 
On a scale of 1 to 5, please indicate the extent to which you think the 
following adjectives are descriptive of (BRAND X). 
 
1 = Not at all Descriptive   
2 = Not Descriptive 
3 = Somewhat Descriptive 
4 = Descriptive 
5 = Very Descriptive 
 
Part 3: Demographic information. Following the brand personality portion of the 
questionnaire, some descriptive information such as education, income, geographic 
location, and occupation (medically related field), and number of visits to a physician in 
the past 12 months was collected. A full copy of the survey is included in Appendix B.  
Data Compilation. Once collected, several steps had to be taken before analyzing 
the data pertaining to the hypotheses. The first step in the analysis involved cleaning the 
data set. A total of 525 participants answered the questionnaire for five brands each, 
resulting in 2625 individual brand ratings. A number of responses were eliminated 
because of incomplete questionnaires or extreme and consistent high or low rating 
patterns (Sung & Kim, 2010). A total of 2245 brand evaluations from 483 respondents 
were retained, resulting in an overall response rate of 35% as detailed in Table 4. Forty-
six percent of respondents were not eligible to respond as they were not familiar with at 









The second step involved arranging the data set for analysis. Consistent with 
brand personality research (Aaker J. , 1997; Geuens, Weijters, & Wulf, 2009), the brand 
personality ratings were “stacked” to form a data array with 2245 rows (483 subjects 
multiplied by the number of brands per subject) with 22 columns (22 brand personality 
items). The variables related to demographics formed a data array with 483 rows.  
The final step involved operationalizing the variables that were used to test the 
relationships proposed in Hypotheses 3 and 4. Table 5 provides a detailed explanation of 




















Response Rates Number of Respondents
Fully completed 35% 483
Not familiar with at least 5 brands 46% 640

















Variable Type Description Measure
Brand 
Familiarity
Independent Based on percentage of 
respondents who were familiar 
with the brand.
The 15 brands were classified into 
two categories: High familiarity 
(over 60% of  respondents 
reporting familiarity with the 
brand), and Low familiarity (less 
than 60% of respondents reporting 
familiarity with the brands). 
Personal 
Experience
Independent Respondents were asked if they 
have ever had a prescription for 
the particular brand. 
Respondents that answered yes 
were deemed to have personal 
experience with the brand and 
respondents that answered no were 
deemed to have no personal 




Independent Annual advertisement 
expenditure per brand was 
established using data from 
Kantar Media (2010) (see 
Appendix A for annual media 
expenditure per brand).  
Advertisement expenditure was 
classified into two categories: 
High advertised brands (annual 
expenditure greater than 
$100mln); and Low advertised 





Independent Recent advertisement exposure 
was assessed using selfreports of 
when was the last time 
respondents had seen an 
advertisement for the brand.
Respondents having seen an 
advertisement within the last 7 
days were considered to have been 





Dependent Respondents were asked to 
indicate on a 5-point Likert 
scale, how likely they were to 
seek a referral for the brand if 
they suffered from the related 
ailment.
The 2245 individual brand ratings 
obtained a score for likelihood to 




Chapter 5: Statistical Analysis & Results 
The statistical analysis and findings of the main consumer study are presented. 
Firstly, statistics describing the nature and breakdown of the data are discussed.  
Secondly, the factor analysis is presented that identifies the underlying dimensions of 
prescription drug brand personality. Finally, results of the multiple regressions analysis 
examining the antecedents and consequences of brand personality are discussed. 
Descriptive Statistics 
The total sample of 483 respondents was well distributed between males and 
females (45% and 55% respectively). The age range was reasonably balanced, with a 
slight preference towards the 45-54-age category. Respondents represented all ranges of 
income although the majority of respondents’ annual income was under $75,000. 
Approximately two thirds of the respondents had completed a post-secondary education. 
The majority of respondents were Caucasian (86%), with the remaining 14% of various 
ethnic backgrounds. Only 10% of respondents worked in a medically related field, and 
the fast majority of respondents (82%) had between one and five visits to a physician on 











Total Sample Descriptive Statistics 
 
 
 The brand familiarity results are reported in Table 7. All of the 15 prescription 
drugs were identified as familiar, and the familiarity distributions were consistent with 
the pretest results. Descriptive statistics for brand familiarity, personal experience, annual 
advertisement expenditures, recent advertisement exposure, and intention to request a 













! " # $! " # %! " # &! " # ' ! " # ( ! " # ) ! " # *! " # +! " # , ! " # $! ! " #








































Note. n = 2245 individual brand evaluations
Variable Descriptive Statistics Variable Descriptive Statistics
Brand 
Familiarity
10 brands were identified as having high 
brand familiarity (Viagra, Lipitor, Cialis, 
Advair, Nexium, Cymbalta, Crestor, 
Chantix, Plavix, Singulair); and 5 brands 
had low brand familiarity (Abilify, 




Of the 2245 responses, approximately 22% 
had seen an advertisement within the last 7 
days (510 respondents). 
Personal 
Experience
Of the 2245 responses, approximately 22% 




The 2245 individual brand ratings 
obtaining a score for likelihood to seek a 
referral (1 = definitely not; 5 = definitely), 




10 brands were identified as having high 
annual advertisement expediture (Lipitor, 
Cialis, Cymbalta, Advair, Abilify, 
Symbicort, Pristiq, Plavix, Chantix, 
Viagra); and the remaining 5 brands had 
low annual expenditure (Crestor, Nexium, 
Seroquel, Enbrel, Singulair). 
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Identification of Brand Personality 
Respondents were asked to indicate the extent to which they felt the listed 
personality traits were descriptive of the particular brand (1 = not at all descriptive; 5 = 
very descriptive). The personality trait scores were combined across all brands and a per-
trait average score was calculated, based on a scale of 1 to 5. As detailed in Table 9, all 
22-traits scored above the mean of three, meaning somewhat descriptive. The results 
confirmed support for Hypothesis 1 indicating that consumers are able to attribute human 
personality traits to prescription drugs.  
 
Table 9 
Personality Trait Average Score (across all brands) 
 
 

























Dimensions of Prescription Drug Brand Personality 
The primary research objective was to identify the underlying dimensions of 
prescription drug brand personality. As such, the analysis focused on perceptions of 
personality dimensions in general, rather than the personality traits of a particular brand. 
Using all brand evaluations (2245), a factor analysis (FA) with default setting for 
principal component was run in SPSS on the 22-item prescription drug brand personality 
scale. 
The FA produced a 2-factor solution as detailed in Table 10. The guidelines on 
number of factors to extract was based on the following criteria (Aaker J. , 1997; Hair, 
Black, Babin, & Anderson, 2010): 
(i) Both factors had eigenvalues greater than one; 
(ii) A significant dip in the Scree plot followed the second factor; 
(iii) The first two factors were the most meaningful and interpretable; and 









Interpreting the Matrix of Factor Loadings. A final factor analysis with 
principle axis extraction, Varimax rotation, and Kaiser normalization was conducted 
which resulted in an easily interpretable two-factor solution, as presented in Table 11. 
 
Factors Initial Eigenvalues % of Variance Cumulative %
1 12.526 56.938 56.938








A visual investigation of the rotated factor solution identified three potential 
issues: (i) certain variables had low factor loadings on the focal factor (<.6); (ii) 
significant loadings on more than one factor, referred to as cross-loadings (>.4); and (iii) 
low communalities (<.5) (Hair, Black, Babin, & Anderson, 2010; Aaker J. , 1997). A 
series of secondary factor analysis with oblique rotation (Quartimun, Bi-Quartimin, and 
Covarimin) was conducted, however, this did not result in a simple structure as defined 
by Thurstone (1946) and did not provide any further insight into factor structure. These 
variables were candidates for possible deletion subject to the variable’s overall 
contribution to the research. Within the context of this study, it was deemed appropriate 
1 2 Communalities
Dependable 0.81 0.28 0.73
Reliable 0.78 0.31 0.70
Stable 0.72 0.36 0.64
Successful 0.71 0.38 0.64
Responsible 0.69 0.43 0.67
Hardworking 0.67 0.46 0.66
Practical 0.66 0.37 0.58
Confident 0.63 0.49 0.64
Precise 0.62 0.47 0.60
Solution Oriented 0.60 0.39 0.51
Caring 0.58 0.49 0.57
Optimistic 0.54 0.50 0.54
Unique 0.23 0.76 0.64
Innovative 0.39 0.73 0.69
Original 0.30 0.68 0.56
Dynamic 0.46 0.59 0.57
Up-to-date 0.48 0.59 0.57
Intelligent 0.57 0.58 0.66
Resourceful 0.55 0.58 0.64
Technical 0.29 0.52 0.35
Serious 0.48 0.50 0.48
Simple 0.46 0.25 0.28
Factor
Note. Variables highlighted in grey are candidates for deletion as they 
have low factor-loadings (< 0.6), and/or high cross-loadings (> 0.4), 




to delete the problematic variables, as they were not well represented by only one of the 
factors and therefore not sufficiently distinct to represent separate concepts. A total of 12 
variables were deleted; hardworking, confident, precise, caring, optimistic, dynamic, up-
to-date, intelligent, resourceful, technical, serious, and simple. 
A subsequent FA was conducted on the remaining 10 variables resulting in a 
similar two-factor solution, based on the previous criteria. A KMO statistics of .937 
indicated that FA was appropriate for the remaining 10 items. The total variance 
explained increased to 71.55%, as seen in Table 12. All items had communalities 
exceeding 0.5 and loaded onto only one factor, with the exception of innovative. 
Innovative had a very slight cross-loading, .69 on the focal factor, and .44 on the 
secondary factor, however was nonetheless retained as the item was deemed meaningful 
within the context of pharmaceutical brand personalities. The final factor solution is 
illustrated in Table 13. The homogeneity of the two dimensions was confirmed by way of 
a FA on each of the individual factors. The results indicated that only one factor should 
















Factors Initial Eigenvalues % of Variance Cumulative %
1 6.124 61.235 61.235









Labeling the Factors. The naming procedure for the two extracted factors 
resulted in the following: 
Competence. This factor label was established based on a comparison of existing 
brand personality dimensions (Kaplan, Yurt, Guneri, & Kurtulus, 2010). Two of the 
variables, reliable and successful, were consistent with items from Aaker’s Competence 
dimension. Four of the items, responsible, practical, reliable, and dependable, were 
consistent with the items of the Conscientiousness dimension of the human personality 
scale. Competence was selected as the factor name as it was very representative of the 
Factor 1 items, such as responsible and dependable.  
Innovativeness. This was a newly emerging dimension that had not been 
documented in previous research. The factor label was intuitively developed based on the 
appropriateness and representativeness of the items of Factor 2 (Hair, Black, Babin, & 
Anderson, 2010). The three variables, innovative, unique, and original had similarly high 
factor loadings, indicating that the three variables had relatively equal importance to the 
dimension. Innovativeness was selected as the most appropriate and descriptive label, as 















Hypothesis 2, suggesting that prescription drugs would be described by the 
personality traits associated with Competence, such as reliable, successful, and 
intelligent, was partially supported. The two underlying dimensions of prescription drug 
brand personality, Competence and Innovativeness, are summarized in Figure 3.  
 
 
Figure 3. Dimensions of Prescription Drug Brand Personality 
 
Reliability. The item-to-total correlations ranged between .44 and .78, and the 
reliability of each dimension was satisfactory (Cronbach's alphas of .92 and .85 for 
Competence and Innovativeness respectively). 
Stability of the Dimensions. The stability of the proposed prescription drug 
brand personality scale was assessed using various subgroups of subjects. This procedure 
ensured that there were not any significant differences in the meaning of the personality 
traits among distinct groups of people and confirmed the generalizability of the scale. 
Principle axis extraction, with Varimax rotation, Kaiser normalization, and unrestricted 
















males (n=1019) versus females (n=1226); (ii) age: younger respondents between the ages 
of 35 and 54 (n=1373) versus older respondents above the age of 55 (n=872); (iii) 
occupation: respondents in a medically related profession (n=204) versus respondents not 
(n=2041); and (iv) a random split sample (n=1122). 
The similarity of the factor structure was assessed qualitatively based on four 
criteria (Aaker J. , 1997): 
(i) The same number of factors were extracted; 
(ii) Consistency of factor structure (traits loaded on the same factors); 
(iii) Similar weights in factor loadings; and 
(iv) Consistency in the level of variance explained by each factor. 
 
The results of the subgroup factor analysis confirmed a two-factor solution, overall 
consistency in the factor structures, loading weights, and variance explained by each 
factor, as described in Table 14. This secondary analysis confirmed that that the 
prescription drug brand personality scale was stable across various subsamples and 












Stability of the Prescription Drug Brand Personality Scale Across Various Subgroups 
 
Antecedents of Brand Personality  
A relationship between the independent variables (brand familiarity, annual 
advertisement expenditure, recent of media exposure, personal experience), and the 
dependent variables (brand personality: Competence and Innovativeness), was 
hypothesized.  
Prior to testing the proposed hypotheses, it was necessary to operationalize brand 
personality into a measurable variable. A composite brand personality score per 
dimension, referred to as a factor score, replaced the individual brand ratings. Each 
respondent received two factor scores, resulting in a total of 2245 factor scores for both 
Competence and Innovativeness.  
Items
Competence Innovative Competence Innovative Competence Innovative Competence Innovative
Dependable 0.83 0.25 0.82 0.23 0.81 0.24 0.85 0.26
Reliable 0.80 0.30 0.80 0.28 0.80 0.28 0.80 0.31
Stable 0.73 0.32 0.73 0.27 0.72 0.31 0.73 0.33
Successful 0.73 0.35 0.73 0.32 0.70 0.32 0.74 0.37
Responsible 0.71 0.37 0.72 0.38 0.71 0.35 0.71 0.39
Practical 0.67 0.33 0.69 0.33 0.68 0.33 0.67 0.34
Solution	Oriented 0.62 0.36 0.61 0.36 0.65 0.31 0.60 0.39
Unique 0.25 0.81 0.23 0.81 0.26 0.79 0.25 0.82
Original 0.33 0.72 0.29 0.70 0.28 0.72 0.36 0.71
Innovative 0.44 0.69 0.46 0.67 0.42 0.70 0.46 0.68
Items Factor
Competence Innovative Competence Innovative Competence Innovative Competence Innovative
Dependable 0.83 0.27 0.83 0.23 0.83 0.26 0.86 0.23
Reliable 0.81 0.29 0.79 0.31 0.81 0.29 0.78 0.37
Stable 0.72 0.33 0.74 0.39 0.73 0.34 0.77 0.25
Successful 0.72 0.36 0.74 0.31 0.72 0.35 0.76 0.33
Responsible 0.70 0.36 0.74 0.33 0.71 0.38 0.71 0.29
Practical 0.66 0.33 0.69 0.35 0.67 0.34 0.69 0.34
Solution	Oriented 0.60 0.34 0.65 0.38 0.61 0.36 0.68 0.31
Unique 0.26 0.80 0.24 0.83 0.25 0.81 0.25 0.87
Original 0.33 0.73 0.42 0.71 0.33 0.71 0.30 0.78
Innovative 0.46 0.68 0.32 0.70 0.44 0.69 0.46 0.63











Two separate multiple regression analysis were conducted in order to test if brand 
familiarity, advertisement level, recent advertisement exposure, and personal experience 
(prior or current usage) significantly predicted participants’ rating of brand personality on 
both the Competence and Innovativeness dimensions. The multicollinearity indices 
(Tolerance and VIF) were within the allowable thresholds (greater than 0.2 and less than 
10 respectively) and did not seem to present any issues for regression analysis (details 
provided in Appendix C). The results of both regressions generated similar findings, 
indicating that the four variables only explained approximately 1.9% of the variance in 
the Competence brand personality ratings (R
2
 = .019, F(4,2190) = 10.55, p<.001), and 
2.6% of the variance in the Innovativeness brand personality ratings (R
2
 = .026, 
F(4,2190) = 14.66, p<.001).  
The independent variables were examined in order to assess their predictive 
powers. Brand familiarity (β = .28, p<.001) and personal experience (β = .11 p<.05) were 
found to be significant predictors of Competence. A significant negative relationship was 
found between annual advertisement expenditure and Competence (β = -.18, p<.001). 
Advertisement expenditure (β = .15, p<.001), recent media exposure (β = .24, p<.001), 
and personal experience (β = .15, p<.05) were found to be significant predictors of 
Innovativeness. Results are summarized in Table 15. Hypotheses 3 (a-d) were partially 








Antecedents of Brand Personality 
 
Consequences of Brand Personality 
A multiple linear regression was used to test if brand personality (Competence 
and Innovativeness) significantly predicted respondents’ intention to request a 
prescription from a physician. The results of the regression indicated that brand 
personality explained 28.2% of the variance in likelihood to request a prescription (R
2
= 
.282, F(2,2242) = 441.39, p<.001).  
A second regression was run, including four additional predictor variables as 
independent variables; brand familiarity, recent media exposure, personal experience, and 
advertisement expenditure. The multicollinearity indices (Tolerance and VIF) were 
within the allowable thresholds (greater than 0.2 and less than 10 respectively) and did 
not seem to present any issues for regression analysis (details provided in Appendix C). 
The results indicated that the additional four variables only accounted for an additional 
four percent in the variance in likelihood to request a prescription (R2 = .322, F(6,2188) = 
173.93, p<.001). 
Model Predictors Coefficients Significance
BPC Brand Familiarity 0.28 0.000 **
Ad Expenditure -0.18 0.000 **
Recent Media Exposure 0.08 0.073
Personal Experience 0.11 0.021 *
BPI Brand Familiarity 0.02 0.733
Ad Expenditure 0.15 0.000 **
Recent Media Exposure 0.24 0.000 **
Personal Experience 0.15 0.001 *
Note. **Levels of statistical significance
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Overall, four variables were found to have a statistically significant relationship 
with intention to request a referral from a physician. The Competence brand personality 
(β = .609, p<.001), Innovativeness brand personality (β = .305 p<.001), personal 
experience (β = .535 p<.001), and recent media exposure (β = .162 p<.05), were found to 
be significant predictors of intention to request a referral from a physician. Brand 
familiarity and advertisement expenditure were not statistically significant. 
Support for Hypothesis 4 was confirmed as it was found that both Competence 
and Innovativeness predicted intentions to request a prescription from a physician. Table 
16 provides a summary of the hypotheses and the outcomes. 
 
Table 16 




H1: Consumers are able to attribute human personality traits to 
prescription drugs. 
Supported
H2: Prescription drugs will be described by personality traits 
associated with Competence, such as reliable, successful, and 
intelligent. 
Partially Supported - Emergence of 
Innovative Dimension
H3a: Consumers are more likely to attribute brand personality to 
prescription drugs that are highly familiar.
Partially Supported (Holds for 
Competence Personality Dimension)
H3b: Consumers are more likely to attribute brand personality to 
prescription drugs that are heavily advertised. 
Partially Supported (Holds for 
Innovative Personality Dimension)
H3c: Consumers are more likely to attribute brand personality to 
prescription drugs for which they have recently seen an 
advertisement.
Partially Supported (Holds for 
Innovative Personality Dimension)
H3d: Consumers are more likely to attribute brand personality to 
prescription drugs for which they have had personal 
experience.
Supported
H4: Consumers are more likely to request a prescription for a brand 





Chapter 6: Discussion 
 
Prescription Drug Brand Personality 
The objective of this research was to draw on the existent brand personality 
construct to develop a framework of prescription drug brand personalities as identified by 
consumers. To identify the brand personality dimensions, a total of 483 subjects rated a 
subset of 15 brands on 22 personality traits. A total of 2245 individual brand ratings were 
generated and analyzed using exploratory principal axis factor analysis. The results 
suggest that consumers do in fact attribute human personality traits to prescription drugs, 
and that prescription drug brand personality as perceived by consumers has two distinct 
dimensions: Competence and Innovativeness. A series of secondary factor analyses on a 
subset of subjects’ confirmed the robustness and generalizability of the scale.   
Prescription Drug Personality Traits 
Consumer Good Brand Personality vs. Prescription Drug Personality. 
Although existing brand personality scales claim to be generalizable to all product 
categories (Geuens, Weijters, & Wulf, 2009), this research emphasizes the need for a 
unique prescription drug brand personality scale. Prior research on consumer goods has 
revealed a multi-dimensional brand personality framework with a high degree of 
consistency with existing human personality scales (Aaker J. , 1997; Geuens, Weijters, & 
Wulf, 2009). The results of pretest 2 reveal that only three dimensions of the Aaker scale 
are relevant (Competence, Excitement, and Sincerity), and only two dimensions of the 
Geuens, Weijters and De Wulf scale emerged (Responsibility and Activity). Some 
similarities exist between consumer goods and prescription brand personalities, for 
example items that form part of the Competence dimension. However, there is limited 
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congruence between the remaining dimensions such as Ruggedness, Sophistication, 
Emotionality, Simplicity, and Aggressiveness. This finding supports the need for an 
industry-specific scale. Using a consumer goods scale to measure prescription drug brand 
personality may be misleading, as some personality traits may be overlooked and result in 
a misrepresented drug personality. 
Negative Traits. A particular finding that emerged in the trait generation phase of 
the research is the relevance of negative personality traits. The vast majority of existing 
brand personality scales have only included positive attributes. Critics have suggested 
that scales are one sided, and similar to human personality traits, brand personality scales 
should also include negative personality traits such as shallow or unintelligent to capture 
the darker side of brand personality (Kaplan, Yurt, Guneri, & Kurtulus, 2010). In light of 
the inherent risks associated with prescription drugs, it is reasonable to surmise that 
consumers might attribute negative personality traits to prescription drugs. In order to 
ensure the scale captured the entire brand personality, in addition to positive personality 
traits, respondents were presented with 13 negative personality traits such as 
irresponsible, untrustworthy, unfriendly, or undependable. Table 4 provides the full list of 
negative personality traits. A frequency distribution revealed that consumers did not 
consider the negative brand personality traits to be characteristics of prescription 
medications and only positive traits were retained for the final study. 
Although additional research is required, there are a few possible reasons why 
negative traits do not seem to apply to prescription drug brand personality. One 
explanation could be that consumers interpret brand personality primarily through 
marketing communications and advertising. The marketing content is controlled by 
  
56 
pharmaceutical companies and is framed in a positive light in order to promote a 
favorable brand identity and foster a positive image. Based on these perceptions, 
consumers may view positive personality traits, versus negative traits, as descriptive of 
prescription medications. A second reasons may be that despite the negative perceptions 
of the industry in general, perhaps consumers maintain a positive image of prescription 
drugs, as they are helpful in curing disease or alleviating suffering. Finally, it may also be 
possible that consumers assume that physicians have a positive opinion of the drugs, 
which in turn influences their views.  
Positive Traits. The emergence of positive personality traits such as reliable, 
dependable, responsible, innovative, original, and solution oriented was not surprising. 
The majority of pharmaceutical communications have used a product-attribute focus, 
portraying effectiveness, symptom control, innovativeness, safety, convenience and cost 
effectiveness as the most common appeals (Bell, Wilkes, & Kravitz, 2000; Blackett & 
Harrison, 2001). The traits found to be most descriptive of prescription drugs are aligned 
with the marketing messages, suggesting that the brand image, as perceived by 
consumers, is consistent with the brand identity portrayed by the pharmaceutical 
marketers. As suggested above, there may also be an implied endorsement from the 
physician when a patient receives a prescription. In other words, consumers assume a 
doctor would not prescribe a “bad drug”.   
Antecedents and Consequences  
The development of a robust scale is a very meaningful contribution in itself; 
however, this research also yields important secondary findings regarding the antecedents 
and consequences of brand personality.  
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Antecedents of Brand Personality. Prior research suggests that brand 
personality can be created indirectly through marketing initiatives and directly though 
usage (Batra, Lenk, & Wedel, 2006). It was therefore hypothesized that brand familiarity, 
advertisement expenditure, recent advertisement exposure, and personal experience (prior 
or current usage) would predict participants' ratings of brand personality. The results 
indicated that only a very limited portion of the variance in brand personality was 
explained by the four-predictor variables (approximately 2%).  
There are two possible reasons why the proposed antecedents only explained a 
small portion of brand personality. Firstly, there may be are other predictor variables that 
were not considered by the current research: for example, the number of years that the 
drug has been on the market; the therapeutic class; severity of side effects; physicians 
perceptions of the brand; status on third party payer’s formulary; or corporate image. 
Pharmaceutical companies allocate a portion of their advertising budgets on campaigns 
designed to promote a positive corporate image, which may influence the development of 
the brand level personality. Perhaps having a favorable corporate image will allow 
consumers to draw a parallel with the brand and will influence the brand personality 
associations.  
Secondly, the limited impact on intention to request a referral may suggest that 
the measures need to be refined. For example, brand familiarity could be explicitly 
measured for each respondent versus assessed on an aggregate basis; advertisement 
exposure and expenditure could differentiate between traditional advertising such as print 
and television, and new mediums such as social media and Internet communications; and 
personal experience could incorporate elements such as prior discussions with a 
  
58 
physician about the specific brand. Multi-item scales may allow for a more sophisticated 
measure, improving the predictive power of the variables. Variables such as familiarity 
and advertisement expenditure were operationalized as a dichotomous variable, which 
reduces the variability in the measure and may reduce the explained variance.  
Although interpretation is tempered by the low explained variance of the models, 
the findings suggest that the antecedents of brand personality will differ by dimension. 
This is a valuable finding for brand managers attempting to build brand personality for 
their prescription drug products. The significant relationships and possible explanations 
are discussed below: 
 Competence Dimension. Consumers are more likely to attribute a Competent 
brand personality to prescription drugs that are highly familiar and for which they have 
had personal experience. They are less likely to attribute a Competent brand personality 
to prescription drugs that are heavily advertised. A discussion of the possible 
explanations for these relationships will follow below.  
 Innovativeness. Consumers are more likely to attribute an Innovative brand 
personality to prescription drugs that are heavily advertised, for which they have recently 
seen an advertisement, and for which they have had personal experience. A discussion of 
the possible explanations for these relationships will follow below. 
Advertisement. Neither annual expenditure nor recent media exposure positively 
influenced the likelihood to attribute brands with a Competent personality. In fact, there 
was a negative relationship between annual media expenditure and Competence. One 
possible explanation is consumers’ skepticism towards mass media. Consumers are 
bombarded by thousands of advertisements on a daily basis resulting in over stimulation, 
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cynicism, and distrust towards mass media. Consumers tend to display a preference 
towards targeted and customized communications. Mass media advertisements may 
therefore deteriorate the perceptions of traits such as dependable, reliable, and 
responsible and result in a less Competent brand personality.  
On the other hand, advertisement expenditure and recent media exposure 
improves the likelihood of attributing an Innovative brand personality. Advertisement 
may be effective in aiding brand recognition, improving recall, and enabling top-of-mind 
awareness. Highly advertised brands may therefore be perceived as state-of-the-art, 
insinuating innovativeness and increasing likelihood of attributing an Innovative brand 
personality.  
Personal Experience. As hypothesized, personal experience (defined as a current 
or past prescription for the brand) has a significant positive relationship with both 
dimensions of brand personality. Consistent with prior research, personal experience is an 
effective way to develop a brand personality (Batra, Lenk, & Wedel, 2006). Given that 
prescription drugs are experiential in nature, meaning consumption is required in order to 
assess quality and impact (Rosenthal, Berndt, Donohue, Epstein, & Frank, 2003), 
marketers are limited in their ability to develop brand personality through usage. In order 
to cultivate a brand personality, marketers will need to create other opportunities for 
personal experience, other than usage. Perhaps personal experience can be fostered 
through physician-patient discussions, which may be influenced by marketers through 
DTCA and physician-focused marketing such as detailing and sampling. Personal 
experience way of physician-patient interaction may be another avenue in which brand 
personality can be developed.   
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Brand Familiarity. Familiarity was found to be a predictor of Competence, but 
not Innovativeness. This is somewhat of an unexpected finding as prior research suggests 
that brand familiarity is a criterion for existence of brand personality (Aaker J. , 1997). If 
consumers are not sufficiently familiar with a brand, they will not be able to attribute a 
brand personality. This finding warrants further investigation. A potential explanation 
may be how brand familiarity was measured within the context of this study, as explained 
above.  
Consequences of Brand Personality. Prior research has shown that brand 
personality allows consumers to develop meaningful relationships with their brands, 
forge strong and favorable associations, and has the power to influence consumer choice. 
The findings of this work suggest a similar relationship, where brand personality can 
increase the likelihood of requesting a prescription from a physician. Overall, four 
variables were found to have a statistically significant relationship with intention to 
request a referral from a physician. The Competence brand personality dimension was 
found to have the strongest influence and accounted for nearly 30% of the variance in 
intention to request a prescription. The inclusion of the remaining three explanatory 
variables, Innovative brand personality, direct usage, and recent media exposure, did not 
substantially improve the explained variation in intention to request a prescription. 
In order to understand what influences a consumer’s intention to request a 
prescription and to develop a comprehensive model, consideration must be given to other 
predictor variables not measured by the current research. Donahue and Berndt (2004) 
investigated the impact of DTCA on choice of antidepressant medication and based their 
research on traditional models of demand for healthcare products and prescription drugs. 
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They hypothesized that the choice of medication may be influenced by three factors: (i) 
individual-level factors such as demographic characteristics like age and gender; (ii) 
features of the medication such as price, length of time on the market, therapeutic 
indications, side effects, and insurance coverage; and (iii) physician preferences which 
are influenced by physician focused marketing strategies such as detailing and sampling 
(Donahue & Berndt, 2004).  
The Competence brand personality dimension showed to be a more significant 
predictor of intention to request a referral than the Innovativeness dimension. Additional 
investigation of this observed relationship is required in order to ensure confounding 
variables do not exaggerate the influence of brand personality on intention to request a 
referral. Of particular interest is the relationship between features of the medication 
(length of time on the market, therapeutic indication, side effects, and insurance 
coverage), and influence on choice. One concern is the potential correlation between 
features of the medication and Competence brand personality. For example, a brand that 
has been on the market for 10 years with limited side effects may be perceived as very 
competent. If this relationship holds, it is difficult to estimate the individual impact of 
brand personality and features of the medication on intention to request a referral.  
The findings of this research suggest that brand personality may influence 
consumers’ choice, supporting consideration for the inclusion of brand personality in the 
established demand models. However, additional research is required in order to 
determine if other variables, for example, features of the medication, are responsible for 




Chapter 7: Managerial & Theoretical Implications 
 
 This research provided empirical support for the existence of prescription drug 
brand personalities as identified by consumers. The main contribution is the development 
of a robust and generalizable scale, and a preliminary understanding of the antecedents 
and consequence of brand personality. The findings of this research will benefits three 
key stakeholders: pharmaceutical marketing practitioners, academics, and consumers. 
Consideration must also be given to the impact on public policy and the physician-patient 
relationship. 
Managerial Implications 
 From a practical standpoint, the development of a prescription drug brand 
personality scale has important implications for the management of brand name 
pharmaceutical drugs and the expansion of branding strategies. Brand personality scales 
have been used as diagnostic instruments that allow marketers to (i) measure and analyze 
consumers’ perceptions of prescription drugs; (ii) compare perceptions of competing 
brands; and (iii) pinpoint alternative positioning strategies (Grohmann, 2009).  
 The prescription drug brand personality scale provides brand managers with a 
measurement tool to assess the effectiveness of their communication messages. 
Pharmaceutical companies spend millions of dollars annually on creating a brand 
identity, however the return on the investment is unclear. Any measurement tool that can 
facilitate assessment will be beneficial. Brand image is the result and interpretation of 
brand identity; however, marketing communications are very often interrupted. This may 
result in a discrepancy between the intended brand identity and the perceived brand 
image. This scale may allow pharmaceutical companies to determine if the prescription 
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drug brand personalities perceived by consumers are consistent with those being 
portrayed by the sender, the pharmaceutical companies. If any disconnects exist, the 
brand managers can make the necessary changes to their strategies to better align the 
brand identity and brand image.  
 Similarly, if the brand personality scale is used as an evaluation tool, it will allow 
the assessment of competing drugs personalities. This could provide insight on how 
brands are currently positioned and identify any opportunities for differentiation. For 
example, if all cholesterol-lowering drugs are perceived to have a Competent brand 
personality, marketers may decide to position their drug with an identity that is consistent 
with the therapeutic class, or differentiate by focusing on other personality traits from the 
Innovativeness dimension.  
 Following the discovery of prescription drug brand personality, the focus shifted to 
understanding how brand personality can be developed. Although preliminary, this 
research suggests that brand personality can be developed indirectly through marketing 
strategies such as advertising, and directly through usage. In addition, the way in which 
brand personality is developed may vary by dimension (Competence or Innovativeness). 
The prescription drug brand personality scale can provide theoretical and applied insight 
into the antecedents of brand personality. Elements of the marketing mix, that include the 
advertising, packaging, user imagery, symbols, public relations efforts, and celebrity 
endorsements could be manipulated to determine the resulting impact on brand 
personality. This may provide managers with meaningful insight on the most effective 




 This research has made a meaningful contribution to the existing work on brand 
personalities. The findings suggest that although existing brand personality scales claim 
to be applicable to all product categories (Geuens, Weijters, & Wulf, 2009), the reality is 
such that these scales may not apply to an industry that is different from consumer goods. 
 In addition to gaining insight on how brand personality can be developed, this 
research provides a glimpse of the potential impact prescription drug brand personality 
has on consumers’ likelihood to request a prescription. These findings can act as a 
foundation on which academics can build a greater understanding of the potential 
influence prescription drug brand personality has on brand evaluations and choice. 
Research on consumer-good brands has shown that brand personality is an asset that can 
create product differentiation (Crask & Laskey, 1990); contribute to more favorable 
evaluations when compared to a generic offering (Upshaw, 1995); and increase brand 
equity, brand loyalty and brand trust (Sung & Kim, 2010). In light of the challenges 
facing the very competitive pharmaceutical industry, brand personality may be a valuable 
marketing strategy. Prescription drug brand personality may have the potential to create a 
sustainable point of differentiation; to build barriers of entry that reduces competition 
from other brand name drugs; to increase loyalty; and to safeguard against the treat of 
generics following patent expiry. The prescription drug brand personality scale will allow 
researchers and marketers to gain a better grasp of the tangible outcomes of brand 
personality. Brand personality can be strategically manipulated and the effect on outcome 
variables such as likelihood to request a prescription, trust, brand evaluations, and 
preference can be explicitly measured.  
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Consumer Related Implications 
Health related concerns might be intimidating and distressing, causing many 
consumers to suffer in silence. The development of prescription drug brand personality 
has the potential to allow consumers to connect with the brand. A prescription drug with 
a personality may seem more approachable and less daunting, giving consumers the 
confidence to take a more active role in their healthcare and seek treatment for previously 
undiagnosed conditions. 
 The empirical confirmation of the existence of brand personality in pharmaceutical 
products has provided incentive for academics and practitioners to investigate further the 
theoretical and applied implications of this construct. With a deeper understanding of 
brand personality, brand managers can begin to strategically cultivate brand personality 
as an effective positioning and differentiation tool. 
Public Policy Related Implications 
The pharmaceutical industry is heavily regulated as a result of the inherent health 
risks associated with the products. The legalization of DTC continues to be debated, as 
there is growing concern for the negative ramifications of encouraging patients to seek a 
prescription for a specific brand. The development of promotional campaigns designed to 
build an emotional appeal and attachment to a prescription brand may be subject to 
ethical scrutiny. Additional research is required in order to better understand the impact 
prescription drug brand personality may have on patients and physicians behaviours. 
Many questions remain unanswered, such as: Is brand personality able to increase the 
emotional attachment to a brand and influence consumers brand preferences? Are 
patients willing to pay more for a brand with a perceptually defined brand personality? 
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What are the implications, both positive and negative, for consumers as well as the 
physician-patient relationship? 
Those in favor of DTC advertisement may suggest that the development of a 
prescription drug brand personality may help educate consumers; empower consumers to 
take a more active role in healthcare; increase treatment for previously undiagnosed 
conditions; or improve public health (Blose & Mack, 2009; National Health Council, 
2002). On the other hand, it may be argued that encouraging patients to seek a particular 
brand may have negative consequences on healthcare relationships and costs. Physicians 
may feel pressured to acquiesce to patient demands, and consumers may pay a premium 
when an equally effective yet cheaper generic offering is available.  
Although we are in the preliminary phase of understanding prescription drug 
brand personality, a counter action by industry regulators and bio-equivalent companies 
could be launched to mitigate any adverse effects on the patient-physician relationship 
and healthcare costs. Informative advertisement campaigns could be designed to 
emphasize physicians’ role as a healthcare advisor, and remind patients that their 
physicians are trained to know what is best for them. Similarly, generic companies can 
also contribute by promoting bio-equivalents and highlighting their effectiveness and 
price advantage. As additional research and information is gathered, public policy makers 






Chapter 8: Limitations 
 
This study makes important theoretical and practical contributions to the 
understanding of prescription drug brand personality, however it is appropriate to discuss 
the limitations of this research.  
Study Design 
Consistent with previous research within the field of brand personality, 
respondents were required to be sufficiently familiar with the brands in order to 
participate in the study. Respondents that were not familiar with any of the brands were 
immediately eliminated. In addition, in order to gather sufficient individual brand ratings, 
each respondent was required to be familiar with a minimum of five prescription drugs in 
order to answer the questionnaire. In the event that they were not familiar with a 
minimum of five brands, they were not permitted to complete the questionnaire. As a 
result of this study design, 46% of respondents were not permitted to answer the 
questionnaire. This presents some limitations on the generalizability of the findings to 
consumers that are not familiar with many prescription drugs. Notwithstanding the 
potential effect on the generalizability of the findings, the study design was deemed 
appropriate, as the priority was to ensure that participants were sufficiently familiar with 
the brands in order to attribute brand personality.  
Data was aggregated across subjects and brands resulting in a “stacked” data 
structure of brand evaluations. As a result of this design, variation between brands and 
subjects was discounted, and meaningful relationships may have been lost. In an ideal 
scenario, each respondent would have provided brand ratings for each of the 15 brands, 
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across the 22 personality traits, resulting in a three-mode data analysis. This design was 
unfortunately not feasible due to risk of fatigue and lack of familiarity with all brands.  
The fact that the analysis is based on personality perceptions of a relatively small 
number of branded prescription drugs that are heavily advertisied or prescribed is another 
limitation.  The number of medical brands is not comparable to that of commercial 
brands, and therefore it was necessary to limit the selection of brands to highly familiar 
brands that have broad exposure in the market. In addition, consumers are not sufficiently 
familiar with the unbranded or generic versions of the brand to attribute a brand 
personality. Therefore, restricting the brand selction to highly advertised or highly 
prescribed branded drugs is justified in this study.  
Trait generation was based on a variety of sources (established brand personality 
and human personality scales). Although care was taken during the trait generation phase 
of the research to ensure meaningful traits were included in the analysis, it is possible that 
certain traits were overlooked. Secondary research could be conducted to evaluate the 
inclusion of other personality traits not originally considered by this research.  
Data 
The sample was limited to residents of the United States as a result of the laws 
governing direct to consumer advertising. This may cause potential issues for 
generalizability across different nationalities and cultures. Prior research suggests that 
brand personality dimensions may vary by nationality and culture (Aaker J. , 1997; 
Aaker, Benet-Martinez, & Garolera, 2001; Sung & Tinkham, 2005) and it would 
therefore be prudent to validate the results with non-U.S. populations. Similarly, the 
sample was restricted to respondents over the age of 35. Within the context of this study, 
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this age category was deemed appropriate given the salience of the product category and 
the fact that the demographic profile of most prescription medication users are over the 
age of 35. Nonetheless, this may cause issues for generalizability to a younger 
population. 
Finally, although the data was thoroughly examined prior to analysis, there may 
have been respondents who responded at random and did not report their true perceptions 
of brand personality. All extreme and consistent high or low rating patterns were 
eliminated, however the potential remains that random responses were included within 
the analysis. This is unfortunately an inherent risk of using an online survey company 




Chapter 9: Areas for Future Research 
 
The early stages of brand personality research focused on the structure and 
measurement scales; however recently, the scope has been broadened to understanding 
the antecedents and consequences of brand personality on brand evaluations and 
consumer behaviour. Research by Louis and Lombart (2010) showed that not all brand 
personality traits have the same influence in the development of lasting consumer-brand 
relationships. Similarly, research by Sung and Kim (2010) suggested that certain 
dimensions of Aaker’s BPS are more likely to influence the level of brand trust than 
brand affect (a positive emotional response). For example, the Sincerity and Ruggedness 
dimensions are more closely related to the level of brand trust, whereas the Excitement 
and Sophistication dimensions relate more closely to brand affect.  
A fruitful area for future research would be to understand how the two dimensions 
of prescription drug brand personality, Competence and Innovativeness, might influence 
brand evaluations and consumer behaviour. Perhaps it could be hypothesized that the 
Competence dimension can increase consumers’ trust in the brand, where as the 
Innovativeness dimension has a higher likelihood of eliciting brand affect. 
From a managerial perspective, additional research in this regard could provide 
marketers with guidelines on how to create and market brand personalities to effectively 
enhance persuasion, increase brand trust and brand affect, and improve overall brand 
evaluations and image. All elements of the marketing mix, including the advertising, 
packaging, pricing, user imagery, symbols, public relations efforts, and celebrity 
endorsements could be manipulated to create and maintain a brand’s personality (Aaker 
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J. , 1997; Sung & Kim, 2010). Understanding which brand personality dimension is best 
suited to improve brand evaluations and optimize purchase intentions is a powerful asset.  
One of the main findings of this research suggests that brand familiarity, 
advertisement, and personal experience are antecedents of brand personality. 
Unfortunately, the proposed variables only accounted for a small portion of the explained 
variance in brand personality, and it is therefore necessary to investigate if other 
antecedents not considered in the current research actually exist. A secondary finding of 
this study suggests that brand personality may influence consumers’ intention to request a 
referral from a physician. Additional research is necessary to clarify and confirm that 
brand personality is responsible for the change in intention to seek a referral, and not 
other variables that are highly correlated with brand personality.  
In order to overcome certain limitations of the current study design and data, 
subsequent research could be done to confirm the stability and generalizability of the 
findings. The scale should be validated with an entirely new sample; with a new set of 
brands; across various cultures and age categories; and investigate the applicability of the 
scale to generic brands.  
The ultimate purpose of any prescription medication is to improve wellbeing. 
Research has shown that simply taking a medication can cause patients to feel better. 
This phenomenon is known as the placebo effect, whereby a patient reports improved 
health, notwithstanding a lack of medically proven progress. Perhaps prescription drugs 
that are able to develop meaningful relationships with their users, by way of brand 
personality, will be more successful in improving the perceived effectiveness of a 
medication. Plausibly, brand personality can enhance perceived effectiveness.  
  
72 
Chapter 10: Conclusions 
The foundation of prescription drug brand personality has been built throughout 
this work. This research has made meaningful contributions to the pharmaceutical 
industry (marketing practitioners and consumers), and to the theoretical study of brand 
personality.  
The major findings are summarized as follows: (i) consumers are able to attribute 
human personality traits to prescription drugs; (ii) prescription drug brand personality is 
characterized by two-dimensions (Competence and Innovativeness); (iii) brand 
personality can be developed through a number of different ways, including brand 
familiarity, advertisement, and personal experience (usage), and the impact of these 
variables will be dependent on the type of brand personality being developed; and finally 
(iv) there is a significant relationship between brand personality and likelihood of 
requesting a prescription from a physician.  
This research has provided pharmaceutical marketers with an effective 
measurement tool that will allow them to assess their current marketing strategies and 
strategically identify potential opportunities. The groundwork for future research has 
been established. Academics can continue to investigate the applicability of the brand 
personality construct to the pharmaceutical industry, and provide a deeper understanding 
of the antecedents and consequences of prescription drug brand personality. Finally, from 
a consumer perspective, prescription drug brand personality may make health-related 
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Appendix A: Most Heavily Advertised & Prescribed Drugs 




Top 20 Most Advertised Prescription Drugs (2010) 
 
 
Rank Brand Sales (bln) Medical Use
1 Lipitor 7.2 High Cholesterol
2 Nexium 6.3 Acid Reflux
3 Plavix 6.1 Blood Thinner
4 Advair 4.7 Asthma, respiratory
5 Abilify 4.6 Mental Health, depression
6 Seroquel 4.4 Mental Health
7 Singulair 4.1 Asthma, respiratory
8 Crestor 3.8 High Cholesterol
9 Actos 3.5 Diabetes
10 Epogen 3.3 Anemia
11 Remicade 3.3 Crohn's Disease, Rheumatoid Arthritis
12 Enbrel 3.3 Rheumatoid Arthritis, Crohn's Disease
13 Cymbalta 3.2 Mental Health, depression
14 Avastin 3.1 Oncology
15 Oxycontin 3.1 Pain Management
16 Neulasta 3.0 Oncology
17 Zyprexa 3.0 Mental Health
18 Humira 2.9 Crohn's Disease, Rheumatoid Arthritis
19 Lexapro 2.8 Mental Health
20 Rituxan 2.8 Oncology
Note. Source: IMS National Sales Perspectives
Rank Brand Media Spending (mln) Medical Use
1 Lipitor 272.0 High Cholesterol
2 Cialis 220.6 Erectile Dysfunction
3 Cymbalta 206.0 Mental Health, depression
4 Advair 200.5 Asthma, respiratory
5 Abilify 155.7 Mental Health, depression
6 Symbicort 152.2 Asthma, COPD, respiratory
7 Pristiq 127.4 Mental Health, depression
8 Plavix 127.3 Blood Thinner
9 Chantix 122.2 Smoking Cessation
10 Lyrica 112.2 Diabetes, fibromyalgia
11 Toviaz 109.5 Bladder Control
12 Viagra 99.9 Erectile Dysfunction
13 Crestor 95.1 High Cholesterol
14 Boniva 85.2 Osteoporosis
15 Lovaza 80.7 High Cholesterol (triglycerides)
16 Seroquel 80.6 Mental Health, depression
17 Enbrel 71.5 Arthritis, psoriasis
18 Spiriva Arthritis 70.7 COPD, respiratory
19 Singulair 70.3 Asthma, allergy, respiratory
20 Simponi 70.1 Arthritis




Appendix B: Research Instrument 
CONSENT TO PARTICIPATE IN THE PRESCRIPTION DRUG BRAND 
PERSONALITY STUDY 
This is to state that I agree to participate in a program of research being conducted by Lea 
Prevel Katsanis, Ph.D. of the Department of Marketing at Concordia University, (514) 





I have been informed that the purpose of the research is to better understand if people use 




I will be presented with a list of 22 personality traits that are often used to describe 
characteristics of people in daily life, but can also be used to describe products and 
services. I will be asked to indicate if I think each of the personality traits are descriptive 
of prescription drugs. 
 
I will answer each question honestly. 
 
Completing the questionnaire should take under fifteen minutes. No personally 
identifiable data will be gathered. 
 
C. RISKS AND BENEFITS 
 
Participants may benefit from further understanding how they describe prescription 
drugs. 
 
D. CONDITIONS OF PARTICIPATION 
 
 I understand that I am free to withdraw my consent and discontinue my 
participation at anytime without consequences. 
 
 I understand that my participation in this study is confidential. 
 
 I understand that the data collected from this survey and analyzed for this study 
may be published. 
 






If at any time you have questions about the proposed research, please contact the study’s 
Principal Investigator: Dr. Lea Katsanis, Department of Marketing, Concordia 
University, at (514) 848-2424 x 2770 or by email lkats@jmsb.concordia.ca. 
  
If at any time you have questions about your rights as a research participant, please 
contact the Research Ethics and Compliance Advisor, Concordia University, at (514) 
848-2424 x 7481 or by email ethics@alcor.concordia.ca. 
 
I HAVE CAREFULLY STUDIED THE ABOVE AND UNDERSTAND THIS 
AGREEMENT. I FREELY CONSENT AND VOLUNTARILY AGREE TO 







SECTION 1 – Screening Questions 
 
Question 1 





 What is your Age? 















Question 3  
 








• You would rate your familiarity either 4 or 5 on a scale of 1 to 5 (1 being very 
unfamiliar, and 5 being very familiar); 
 
CHECK ALL THAT APPLY: 
 
 Abilify  Advair 
 Chantix  Cialis 
 Crestor  Cymbalta 
 Enbrel  Lipitor 
 Nexium  Plavix 
 Pristiq  Seroquel 
 Singulair  Symbicort 




Of the prescription drugs listed below, please indicate which 5 brands you are MOST 
familiar with. 
 
 Abilify  Advair 
 Chantix  Cialis 
 Crestor  Cymbalta 
 Enbrel  Lipitor 
 Nexium  Plavix 
 Pristiq  Seroquel 
 Singulair  Symbicort 









SECTION 2 - Prescription Drug Brand Personality 
 
Question 1 
The following adjectives are mostly used to describe characteristics of people in daily 
life. However, some of them can be used to describe products, services, or prescription 
medications. This may sound unusual, but we would like you to think of Brand 1 as if it 
was a person. We are interested in finding out which personality traits or human 
characteristics come to mind. To assist you, we have preselected 22 personality traits, and 
would ask that you please indicate the extent to which you think that each of the 
personality traits describe Brand 1. 
 
For example, you might think that the human characteristics associated with Pepto 
Bismol are kind, warm, caring, soothing, gentle, trustworthy and dependable. The human 
characteristics associated with Dr. Pepper might be non-conforming, fun, interesting, 
exciting, and off-beat.  
 
On a scale of 1 to 5, please indicate the extent to which you thing the following adjectives 
are descriptive of Brand 1. 
 
 
1 = Not at all Descriptive   
2 = Not Descriptive 
3 = Somewhat Descriptive 
4 = Descriptive 
5 = Very Descriptive 
 
 
 Original 1     2     3     4     5  Dependable 1     2     3     4     5 
 Technical 1     2     3     4     5  Simple 1     2     3     4     5 
 Optimistic 1     2     3     4     5  Resourceful 1     2     3     4     5 
 Hard working 1     2     3     4     5  Stable 1     2     3     4     5 
 Practical 1     2     3     4     5  Caring 1     2     3     4     5 
 Reliable 1     2     3     4     5  Up-to-date 1     2     3     4     5 
 Confident 1     2     3     4     5  Intelligent 1     2     3     4     5 
 Dynamic 1     2     3     4     5  Unique 1     2     3     4     5 
 Responsible 1     2     3     4     5  Solution Oriented 1     2     3     4     5 
 Innovative 1     2     3     4     5  Precise 1     2     3     4     5 
 Successful 1     2     3     4     5  Serious 1     2     3     4     5 








When was the last time you saw an advertisement for Brand 1? 
 
• In the past 7 days 
• In the past 30 days 
• In the past 180 days 
• In the past 365 days 
• More than a year ago 
• Never 




Where did you first learn about Brand 1? 
 
• Medical Professional 
• Family or Friend 
• Advertisement 
• Internet 
• Social media 
• Other, please specify: 
 
Question 4 




• Prefer not to answer 
 
Question 5 



















• Prefer not to answer 
 
Question 7 
If you had this medical condition, how likely would you be to seek a prescription from a 
medical professional for Brand 1? 
 
 
1 = Definitely Not 
2 = Not Likely 
3 = Likely 
4 = Very Likely 
5 = Definitely 
 
 
SECTION 3 - Demographic Information 
 
Question 1 
What is the highest level of education that you have completed? 
 
• High school diploma or less 




What is your race / ethnic background? 
 
• White / Caucasian 
• Spanish / Hispanic / Latino 
• Black / African American 
• Asian 
• Pacific Islander 
• Native American 
• Other 






What is your total household income? 
 
• Under $20,000 
• $20,000 - $29,999 
• $30,000 - $39,999 
• $40,000 - $49,999 
• $50,000 - $74,999 
• $75,000 - $99,999 
• $100,000 or more 




Which state do you live in? 
 
Question 5 
In the past 12 months, how many times have you been to see a physician? 
 
• 1 - 5 Times 
• 6 – 9 Times 
• 10 Times or more 
 
Question 6 



















Appendix C: Statistical Outputs 
 






Extraction Method: Principal Axis Factoring. 
 
KMO and Bartlett's Test 
Kaiser-Meyer-Olkin Measure of Sampling Adequacy. .980 
Bartlett's Test of Sphericity 
















Solution Oriented .526 















Extraction Method: Principal Axis Factoring. 
 
 
Total Variance Explained 
Factor Initial Eigenvalues Rotation Sums of Squared Loadings 
Total % of Variance Cumulative % Total % of Variance Cumulative % 
1 12.526 56.938 56.938 7.317 33.257 33.257 
2 1.174 5.338 62.276 5.595 25.431 58.688 
3 .767 3.488 65.764    
4 .759 3.451 69.215    
5 .598 2.717 71.932    
6 .582 2.646 74.578    
7 .538 2.447 77.025    
8 .471 2.142 79.167    
9 .438 1.993 81.160    
10 .401 1.824 82.983    
11 .381 1.730 84.714    
12 .375 1.705 86.419    
13 .363 1.649 88.068    
14 .346 1.574 89.642    
15 .329 1.494 91.135    
16 .324 1.474 92.610    
17 .310 1.410 94.020    
18 .300 1.365 95.385    
19 .282 1.282 96.668    
20 .275 1.248 97.916    
21 .242 1.101 99.017    






Extraction Method: Principal Axis Factoring.  
 Rotation Method: Varimax with Kaiser Normalization.
a
 





















Original .302 .682 
Confident .628 .494 
Simple .467 .249 
Intelligent .566 .582 
Technical .294 .515 
Dynamic .475 .585 
Unique .231 .763 
Optimistic .541 .501 
Responsible .692 .434 
Stable .716 .357 
Solution Oriented .596 .395 
Hard Working .670 .456 
Resourceful .553 .575 
Innovative .393 .730 
Caring .581 .487 
Precise .616 .471 
Practical .664 .368 
Successful .705 .377 
Up-to-date .481 .586 
Serious .481 .502 
Reliable .780 .308 









Extraction Method: Principal Axis Factoring. 
 
 
Extraction Method: Principal Axis Factoring 
KMO and Bartlett's Test 
Kaiser-Meyer-Olkin Measure of Sampling Adequacy. .937 
Bartlett's Test of Sphericity 

















Total Variance Explained 
Factor Initial Eigenvalues Rotation Sums of Squared Loadings 
Total % of Variance Cumulative % Total % of Variance Cumulative % 
1 6.124 61.235 61.235 4.092 40.920 40.920 
2 1.032 10.319 71.554 2.396 23.959 64.879 
3 .520 5.203 76.757    
4 .495 4.949 81.706    
5 .378 3.783 85.489    
6 .342 3.420 88.910    
7 .326 3.261 92.170    
8 .298 2.983 95.153    
9 .267 2.669 97.822    






Extraction Method: Principal Axis Factoring.  
 Rotation Method: Varimax with Kaiser Normalization.
a
 









Original .327 .716 
Unique .252 .809 
Innovative .442 .691 
Responsible .712 .371 
Stable .726 .322 
Solution Oriented .619 .356 
Practical .671 .334 
Successful .725 .346 
Reliable .802 .299 




Regression Analysis – Model 1 
 
Independent Variables: 
 Brand Familiarity (High = 1 / Low = 0) 
 Annual Advertising Expenditure (High = 1 / Low = 0) 
 Prior Use (Yes = 1 / No = 0) 
 Recent Media Exposure (Last 7 days = 1 / Other = 0) 
 
Dependent Variables: 
 BPC (Brand Personality – Competence) (Factor Score) 
 
 
a. Dependent Variable: BPC 
b. All requested variables entered. 
 
 
a. Predictors: (Constant), Usage, Familiarity, RecentAd, Adexpenditure 
b. Dependent Variable: BPC 
 
a. Dependent Variable: BPC 






















Model R R Square Adjusted R 
Square 









Model Sum of 
Squares 
df Mean Square F Sig. 
1 
Regression 35.905 4 8.976 10.548 .000
b
 
Residual 1863.582 2190 .851   





a. Dependent Variable: BPC 
 
 
a. Dependent Variable: BPC 
 
 


















t Sig. Collinearity 
Statistics 
B Std. Error Beta Tolerance VIF 
1 
(Constant) -.157 .068  -2.308 .021   
Familiarity .278 .062 .095 4.460 .000 .992 1.008 
Adexpenditure -.179 .045 -.085 -3.998 .000 .983 1.017 
RecentAd .080 .045 .038 1.793 .073 .989 1.012 














1 3.354 1.000 .01 .01 .02 .03 .02 
2 .743 2.124 .00 .00 .01 .16 .82 
3 .652 2.267 .01 .01 .03 .79 .10 
4 .197 4.122 .03 .16 .85 .00 .04 





 Minimum Maximum Mean Std. Deviation N 
Predicted Value -.3356881 .3103422 .0053488 .12792604 2195 
Residual -3.43835378 2.09467340 0E-8 .92162863 2195 
Std. Predicted Value -2.666 2.384 .000 1.000 2195 




Regression Analysis – Model 2 
 
Independent Variables: 
 Brand Familiarity (High = 1 / Low = 0) 
 Annual Advertising Expenditure (High = 1 / Low = 0) 
 Prior Use (Yes = 1 / No = 0) 
 Recent Media Exposure (Last 7 days = 1 / Other = 0) 
Dependent Variables: 



























a. Dependent Variable: BPI 






Model R R Square Adjusted R 
Square 




 .026 .024 .87544679 
 
a. Predictors: (Constant), Usage, Familiarity, RecentAd, 
Adexpenditure 





Model Sum of 
Squares 
df Mean Square F Sig. 
1 
Regression 44.946 4 11.237 14.661 .000
b
 
Residual 1678.432 2190 .766   
Total 1723.378 2194    
 
a. Dependent Variable: BPI 






























t Sig. Collinearity 
Statistics 
B Std. Error Beta Tolerance VIF 
1 
(Constant) -.223 .064  -3.467 .001   
Familiarity .020 .059 .007 .342 .733 .992 1.008 
Adexpenditure .148 .042 .074 3.490 .000 .983 1.017 
RecentAd .240 .043 .120 5.636 .000 .989 1.012 
Usage .152 .045 .072 3.419 .001 .992 1.008 
 














1 3.354 1.000 .01 .01 .02 .03 .02 
2 .743 2.124 .00 .00 .01 .16 .82 
3 .652 2.267 .01 .01 .03 .79 .10 
4 .197 4.122 .03 .16 .85 .00 .04 
5 .053 7.985 .95 .82 .08 .02 .02 
 





 Minimum Maximum Mean Std. Deviation N 
Predicted Value -.2234721 .3372518 .0015567 .14312897 2195 
Residual -2.77116323 1.96929300 0E-8 .87464839 2195 
Std. Predicted Value -1.572 2.345 .000 1.000 2195 
Std. Residual -3.165 2.249 .000 .999 2195 
 




Regression Analysis – Model 3 
 
Independent Variables: 
 BPC (Brand Personality – Competence) (Factor Score) 
 BPI (Brand Personality – Innovativeness) (Factor Score) 
 Brand Familiarity (High = 1 / Low = 0) 
 Annual Advertising Expenditure (High = 1 / Low = 0) 
 Prior Use (Yes = 1 / No = 0) 
 Recent Media Exposure (Last 7 days = 1 / Other = 0) 
 
Dependent Variables: 


























a. Dependent Variable: Referral 





Model R R Square Adjusted R 
Square 




 .322 .320 1.058 
a. Predictors: (Constant), RecentAd, BPC, Usage, Familiarity, 
Adexpenditure, BPI 





Model Sum of 
Squares 
df Mean Square F Sig. 
1 
Regression 1162.683 6 193.781 173.193 .000
b
 
Residual 2448.082 2188 1.119   
Total 3610.765 2194    
a. Dependent Variable: Referral 
























Model Unstandardized Coefficients Standardized 
Coefficients 
t Sig. Collinearity Statistics 
B Std. Error Beta Tolerance VIF 
1 
(Constant) 3.033 .078  38.816 .000   
BPC .609 .025 .442 24.594 .000 .961 1.040 
Familiarity .140 .072 .035 1.946 .052 .983 1.017 
Adexpenditure -.011 .052 -.004 -.209 .835 .969 1.032 
Usage .535 .054 .175 9.895 .000 .985 1.015 
BPI .305 .026 .211 11.690 .000 .954 1.048 
RecentAd .162 .052 .056 3.119 .002 .974 1.027 





Model Dimension Eigenvalue Condition Index Variance Proportions 
(Constant) BPC Familiarity Adexpenditure Usage BPI RecentAd 
1 
1 3.358 1.000 .01 .00 .01 .02 .02 .00 .03 
2 1.159 1.702 .00 .39 .00 .00 .01 .41 .01 
3 .876 1.957 .00 .54 .00 .00 .01 .47 .04 
4 .736 2.136 .00 .05 .00 .01 .80 .01 .15 
5 .627 2.315 .01 .00 .01 .03 .11 .10 .76 
6 .193 4.176 .03 .02 .16 .86 .03 .02 .00 
7 .052 8.016 .95 .00 .82 .08 .02 .00 .02 





 Minimum Maximum Mean Std. Deviation N 
Predicted Value .97 4.89 3.32 .728 2195 
Residual -3.535 3.273 .000 1.056 2195 
Std. Predicted Value -3.229 2.156 .000 1.000 2195 
Std. Residual -3.342 3.094 .000 .999 2195 




Regression Analysis – Model 3 – Stepwise Multiple Regression 
 
Independent Variables: 
 BPC (Brand Personality – Competence) (Factor Score) 
 BPI (Brand Personality – Innovativeness) (Factor Score) 
 Brand Familiarity (High = 1 / Low = 0) 
 Annual Advertising Expenditure (High = 1 / Low = 0) 
 Prior Use (Yes = 1 / No = 0) 
 Recent Media Exposure (Last 7 days = 1 / Other = 0) 
 
Dependent Variables: 








Model R R Square Adjusted R 
Square 




 .236 .236 1.122 
2 .536
b
 .287 .286 1.084 
3 .564
c
 .318 .317 1.060 
4 .566
d
 .321 .320 1.058 
a. Predictors: (Constant), BPC 
b. Predictors: (Constant), BPC, BPI 
c. Predictors: (Constant), BPC, BPI, Usage 
d. Predictors: (Constant), BPC, BPI, Usage, RecentAd 





Model Sum of 
Squares 
df Mean Square F Sig. 
1 
Regression 852.317 1 852.317 677.603 .000
b
 
Residual 2758.448 2193 1.258   
Total 3610.765 2194    
2 
Regression 1036.602 2 518.301 441.354 .000
c
 
Residual 2574.163 2192 1.174   
Total 3610.765 2194    
3 
Regression 1148.402 3 382.801 340.614 .000
d
 
Residual 2462.363 2191 1.124   
Total 3610.765 2194    
4 
Regression 1158.442 4 289.610 258.631 .000
e
 
Residual 2452.324 2190 1.120   
Total 3610.765 2194    
a. Dependent Variable: Referral 
b. Predictors: (Constant), BPC 
c. Predictors: (Constant), BPC, BPI 
d. Predictors: (Constant), BPC, BPI, Usage 














Model Unstandardized Coefficients Standardized 
Coefficients 
t Sig. Collinearity Statistics 
B Std. Error Beta Tolerance VIF 
1 
(Constant) 3.315 .024  138.491 .000   
BPC .670 .026 .486 26.031 .000 1.000 1.000 
2 
(Constant) 3.315 .023  143.318 .000   
BPC .626 .025 .454 24.910 .000 .980 1.020 
BPI .330 .026 .228 12.527 .000 .980 1.020 
3 
(Constant) 3.191 .026  123.670 .000   
BPC .614 .025 .445 24.969 .000 .978 1.022 
BPI .314 .026 .217 12.149 .000 .976 1.024 
Usage .538 .054 .177 9.974 .000 .993 1.007 
4 
(Constant) 3.151 .029  108.558 .000   
BPC .613 .025 .445 24.987 .000 .978 1.023 
BPI .304 .026 .210 11.712 .000 .962 1.040 
Usage .534 .054 .175 9.914 .000 .992 1.008 
RecentAd .154 .052 .053 2.994 .003 .983 1.017 





Model Beta In t Sig. Partial 
Correlation 
Collinearity Statistics 





 1.377 .169 .029 .993 1.008 .993 
Adexpenditure .008
b
 .447 .655 .010 .993 1.007 .993 
Usage .190
b
 10.421 .000 .217 .997 1.003 .997 
BPI .228
b
 12.527 .000 .258 .980 1.020 .980 
RecentAd .085
b




 1.535 .125 .033 .992 1.008 .973 
Adexpenditure -.012
c
 -.670 .503 -.014 .985 1.015 .972 
Usage .177
c
 9.974 .000 .208 .993 1.007 .976 
RecentAd .058
c




 1.740 .082 .037 .992 1.008 .971 
Adexpenditure .002
d
 .140 .889 .003 .979 1.022 .967 
RecentAd .053
d




 1.936 .053 .041 .988 1.012 .962 
Adexpenditure -.001
e
 -.066 .947 -.001 .974 1.027 .954 
a. Dependent Variable: Referral 
b. Predictors in the Model: (Constant), BPC 
c. Predictors in the Model: (Constant), BPC, BPI 
d. Predictors in the Model: (Constant), BPC, BPI, Usage 





Model Dimension Eigenvalue Condition Index Variance Proportions 
(Constant) BPC BPI Usage RecentAd 
1 
1 1.006 1.000 .50 .50    
2 .994 1.006 .50 .50    
2 
1 1.141 1.000 .00 .43 .43   
2 1.000 1.068 1.00 .00 .00   
3 .859 1.152 .00 .57 .57   
3 
1 1.490 1.000 .25 .01 .01 .25  
2 1.135 1.146 .02 .41 .41 .00  
3 .859 1.317 .00 .57 .56 .00  
4 .516 1.700 .73 .00 .01 .74  
4 
1 1.868 1.000 .13 .00 .01 .12 .12 
2 1.135 1.283 .01 .42 .41 .00 .00 
3 .869 1.467 .00 .54 .51 .02 .02 
4 .720 1.611 .00 .03 .04 .56 .41 
5 .408 2.141 .85 .00 .04 .30 .44 





 Minimum Maximum Mean Std. Deviation N 
Predicted Value 1.01 4.86 3.32 .727 2195 
Residual -3.514 3.304 .000 1.057 2195 
Std. Predicted Value -3.181 2.126 .000 1.000 2195 
Std. Residual -3.320 3.122 .000 .999 2195 
a. Dependent Variable: Referral 
 
